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ABSTRACT 
 
Chronic kidney disease (CKD) is a major cause of morbidity and mortality among 
kidney patients in Newfoundland and Labrador (NL). This study aims to investigate the 
burden of CKD across geographic areas in NL and the utilization pattern for nephrology 
services. The ultimate goal is to inform future service planning in NL.  
This is a retrospective cohort study of 40,465 CKD patients’ administrative data 
recorded over a 5-year period (2011-15). We compared the differences in nephrology 
service accessibility and frequency of nephrologist visit follow-up among the four health 
regions. P<0.05 was considered statistically significant. 
This study found that only 7.3% of NL CKD patients were in contact with 
nephrologists within one year of CKD being identifiable based on estimated glomerular 
filtration rate (eGFR). Male CKD patients have a 1.4-fold (OR, 1.4; 95% CI, 1.3-1.5 (p < 
0.05) higher chance of seeing a nephrologist than female CKD patients. Among diabetic 
patients, only 12.8% of patients were tested for their urine albumin-creatinine ratio. On 
the other hand, only 4.5% of all CKD patients had a urine analysis performed. This is an 
underutilization of urine testing, which is a key diagnostic test that care-providers are 
failing to offer. Except for in the Eastern Regional Integrated Health Authority (ERIHA), 
patients from all other health regions faced difficulties in accessing nephrology care in 
their own regions.  
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Development of telehealth and e-health programs and decentralizing CKD early 
detection and risk identification and care by a robust kidney outreach program would be 
useful for optimal CKD care in NL. 
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Chapter 1: Introduction and Background 
 
1.1 Introduction 
Practicing nephrologists in Newfoundland and Labrador (NL) frequently suggest 
that kidney disease prevalence has increased over the past two decades.1,2 Although this 
assertion is based on anecdotal evidence, if proven correct, it may have a significant 
impact on the future planning and development of kidney services in the province. The 
prevalence of chronic kidney disease (CKD) in NL needs to be identified while 
anticipating the needs for kidney care services throughout the provincial health care 
system. 
 
1.2 The current structure of the provincial health care system  
Newfoundland and Labrador is one of the provinces located as part of mainland 
Canada. The province is divided into four health authorities, namely Eastern, Central, 
Western, and Labrador-Grenfell regional integrated health authorities (RIHA). There are 
kidney care services in all four health authorities, ranging from travelling nephrology 
clinic to kidney replacement therapy (RRT). Although the best possible service is to have 
a full range of kidney care, it is not practical to deliver the kidney care service to every 
community because of the various geographic distribution of the relatively small 
population throughout the province. Nephrology services are therefore mainly centered 
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in St. John’s and Corner Brook in the eastern and western health region, respectively, 
where the majority of the NL population lives. There are two nephrologists in Corner 
Brook, and the rest of the province’s eight nephrologists are in St. John’s. There are 
some travelling clinics providing nephrology services across the regions. There is also a 
well-established telehealth system in the province; it is used regularly during the dialysis 
unit follow-ups, but the kidney clinics do not often use it. There is an e-consult service 
available, but most of the nephrologists are not participating. This current structure of 
kidney service delivery limits patients’ in-person follow-up, especially in central and 
Grenfell-Labrador health regions and other remote locations as well. Also, it often 
displaces patients and families to areas that offer appropriate kidney care services.  
 
1.3 Chronic kidney disease  
Chronic Kidney Disease (CKD) is defined as the presence of reduced kidney 
function and/or evidence of kidney damage for a period of three months or more.3,4 
Evidence of kidney damage includes albuminuria, abnormal pathology/radiology or 
reduced kidney function (an estimated glomerular filtration rate (eGFR) <60 
mL/min/1.73m2).5 CKD has become a major public health challenge in the last decade 
due to its increased prevalence and strong association with kidney failure (end-stage 
kidney disease, ESKD).6,7,8 According to the Kidney Disease Improving Global Outcomes 
(KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic 
Kidney Disease9, CKD can be classified into the following six stages: G1-2, G3a-b, G4-5. 
3 
 
This KDIGO international system is a 2D matrix (Figure 1) that integrates the three levels 
(A1-3) of albuminuria (urine albumin to creatinine ratio in mg/g or mg/mmol) and the 
level of kidney function ((measured by either eGFR, or, measured GFR (mGFR)). The 
matrix describes the risk stratification of the severity of CKD progressing up to ESKD. For 
example, a patient whose eGFR is in the category of G3b (Moderately to severely 
decreased kidney function) and whose albuminuria is severely increased (A3: >300mg/g 
or >30mg/mmol), would be referred to as a CKD stage G3bA3, meaning he would have a 
very high risk of progressing to kidney failure.10 
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CKD=chronic kidney disease; GFR=glomerular filtration rate; KDIGO=Kidney Disease: 
Improving Global Outcomes 
 
Figure 1: Risk stratification chart for prognosis of CKD by eGFR and albuminuria 
categories (figure adapted from original source, used with permission)11 
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1.4 CKD risk factors  
One major cause of kidney function impairment is scarring or fibrosis of the 
blood vessels coiled within the glomeruli, a cluster of capillaries located inside the 
kidneys. The scarred vessels limit blood flow, and thus, the glomeruli cannot filter out 
waste products efficiently.12,13 This scarring process is common in patients with high 
blood pressure14 and diabetes15, which places them at a higher risk for CKD. Diabetes, 
which is characterized by increased blood sugar levels, is caused by the body’s inability 
to produce or use insulin, a blood glucose regulating hormone.16 High blood sugar levels 
signal mesangial cells within glomeruli to produce scar tissue which then interrupts 
blood flow through the glomeruli.17,18,19  
In hypertension, the increased blood pressure causes thickening of the afferent 
arteriole in order to withstand the pressure and this thickening narrows the arteriolar 
lumen. As the lumen narrows blood and oxygen flow lessen causing ischemic injury to 
the nephron’s glomerulus. Immune cells like macrophages and foam cells enter the 
damaged glomerulus and stimulate the production of transforming growth factor beta1. 
This growth factor causes mesangial cells to convert into mesangioblasts, the more 
immature stem cell state of mesangial cells. Mesangioblasts secrete extracellular 
structural matrix. Excessive extracellular matrix causes hardening and scarring of the 
glomerulus known as glomerulosclerosis, which limits the nephron’s ability to filter the 
blood and leads to chronic kidney disease over time.20 
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Fifty percent of all diabetic patients21 and ~20% of hypertensive patients22 
worldwide are estimated to develop CKD during their lifetime. More than 75 percent of 
all cases of stage 3-5 CKD in Canada are attributable to these two diseases.23 Other 
common risk factors such as obesity, cardiovascular disease and family history of end 
stage kidney disease also contribute to higher risks for CKD.24  
 
1.5 CKD biomarkers 
The two essential laboratory measures necessary to diagnose CKD clinically are urine 
albumin to creatinine ratio (UACR) and the estimated glomerular filtration rate25 The 
UACR which measures albumin excretion, can be measured using a spot urine test 
(preferably from the first-morning void). A UACR exceeding >30 mg/g indicates 
albuminuria, which is one of the strongest predictors of declining kidney function.26 It 
has been recommended that UACR should be tested annually in all patients with type2 
diabetes and patients who have had type 1 diabetes for five years or longer.27 
Another important test for identifying CKD is eGFR. For patients who are 
clinically stable and non-hospitalized, eGFR is considered the best indicator to measure 
kidney function.28 As serum creatinine (Scr) is the primary component of the eGFR 
measurement, there are numerous formulas that exist to calculate eGFR by using Scr.29 
One of the most widely used formulas is “The Modification of Diet in Kidney Disease” 
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(MDRD) equation, which encompasses data including age, sex, race, and serum 
creatinine.30  
eGFRMDRD = 186 × (Scr/88.4)-1.154 × Age-0.203 × [1.21 if Black] × [0.742 if Female]  
(where, Scr = serum creatinine in µmol/L)31 
 
The standard equation is applicable to male Caucasians and has an adjustment 
for females and black individuals. For females, the equation multiplies the GFR 
estimates by 0.742. This is because average muscle mass and creatinine generation rate 
in women are lower relative to men. Also, for black individuals, the equation will 
multiply the eGFR estimate by 1.21 due to the fact that black individuals have higher 
average muscle mass and creatinine generation rates compared to Caucasians.31  
Although the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF KDOQI) recommended eGFRMDRD in CKD due to an accuracy of 92% of 
values being within 30% of true GFR32, the grading of CKD should also be based on 
whether the UACR is more than 30mg/g creatinine or the eGFR is less than 60 
ml/min/1.73m2 on two separate occasions tested three or more months apart.33 
Another widely used creatinine-based equation is the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI).34 When eGFR value is anticipated to be >60 
mL/min/1.73 m², this recently formulated equation provides more accurate results.35  
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As alternatives to creatinine-based equations, a number of researchers have 
proposed GFR estimates based on other molecules such as cystatin C (Cys C), which is 
less influenced by muscle mass than serum creatinine. It provides an index of the 
glomerular filtration rate, especially in population subgroups including very obese, 
elderly, malnourished, vegetarians, etc. in whom serum creatinine may be 
inconsistent.36 
CKD may not be identified based on a single or isolated UACR or eGFR 
measurement.37 Age38, along with, kidney function stability39 play an important role in 
an inconsistent eGFR reading. Many health conditions may present with fluctuating 
serum creatinine levels, which may lead to the under or overestimation of eGFR.40,41 
Hospitalization42, acute kidney injury (AKI)43, major limb amputation44, hepatic 
cirrhosis45, and severe obesity46 are among such health conditions. False positive results 
may also be seen in both very young and old age groups.47 Thus, the eGFR test for CKD 
may not always be accurate and limitation free.48  
 
1.6 Prevalence of CKD 
1.6.1 Global trends 
There has been an alarming increase in the prevalence of CKD globally. In 2015, 
there were 1.2 million deaths due to CKD worldwide compared to 0.93 million in 2005, a 
31.7% rise in 10 years (95% CI 27.7-35.6; p<0.05). The estimation of 1.2 million deaths 
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due to CKD by the Global Burden of Disease (GBD) study in 2015 makes it the 17th 
leading cause of death, up from 21st in 2005 and 25th in 1990.49 Accounting for the 
shifting age structure of the global population, by contrast, the rise of age-standardized 
death rates due to CKD was only 1.2% (95% CI -1.9-4.0; p>0.05).49  
The Studies indicated that the global mean CKD prevalence in females [14.6% (12.7-
16.7%)] was more common than in males [12.8% (10.8–11.9%)], irrespective of CKD 
stages50, possibly due to the global increase in sex-related differences in obesity51, and 
other contributing factors such as high blood pressure52 and diabetes mellitus53.  
According to the Global Kidney Health Atlas (GKHA)54 project, survey from 125 
countries (93% of the global population) showed that CKD was common throughout the 
world: 7% of the total population in South Asia, 8% in Africa, 11% in North America, and 
12% in Europe, the Middle East, East Asia and Latin America. It is more common in high-
income countries: 24% in Belgium and Saudi Arabia, 18% in Poland, 17% in Germany, 
16% in UK and Singapore, and 14% in the USA, with the exceptions of Norway and the 
Netherlands at only 5%, than low-and-middle-income countries (LMICs). However, a 
disproportionate increase in CKD prevalence rates was seen in LMICs as well.55 The 
fastest CKD prevalence rate increase has also been seen in LMICs (especially Asia and 
Africa), where most people with CKD are likely to live and where the annual prevalence 
rate of CKD related death has increased by 5% from 1990-2013.56 The increase in CKD 
prevalence rates in developing countries follows the trends of urbanization and lifestyle 
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changes, including increasingly sedentary lifestyles, less physically demanding work, and 
the global nutrition transition which is marked by increased intake of energy-dense but 
nutrient-poor foods (often high in sugar and saturated fats).57,58,59 
The number of people with CKD is increasing around the world. In the USA, if the 
current trend continues, it is projected that the prevalence of CKD (in adults ≥30 years) 
may increase from its current rate of 13.2% to 14.4% by 2020 and 16.7% by 2030. 
Furthermore, for adults aged 30-49, the remaining lifetime incidence of CKD is 54%, 
suggesting more than half of the adult population will have CKD in their lifetime.60 
However, fortunately, CKD is largely preventable; for example, for diabetic patients, 
controlling blood sugar can help to prevent the onset of early-stage CKD.61 
 
1.6.2 The Canadian perspective 
The Kidney Foundation of Canada estimates that 1 in 10 Canadians has kidney 
disease. The Foundation also reports that millions of individuals are at risk of kidney 
disease according to a 2016 annual report. CKD prevalence has increased tremendously 
over the past two to three decades in the Canada.62 
According to the results of a nationally representative heath measures survey (2007-
09), approximately 12.5% of the Canadian population is affected by CKD.23 Arora et al. 
found that about 2.9 million Canadian adults were living with stage 3-5 CKD. The 
prevalence of CKD is markedly higher (31%) in those aged 65 or older. The most 
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common causes of CKD are diabetes and high blood pressure followed by other health 
conditions and kidney diseases. Elliot et al.63 note that the majority of patients with CKD 
are treated in primary care settings. The remaining relatively small number of severe 
cases are seen by nephrologists. 
 
1.6.3 Prevalence of CKD in the Indigenous population 
Studies have shown that the Indigenous population suffers from increased risk of 
undiagnosed and untreated CKD compared to non-Indigenous population.64 In 
Indigenous communities, the prevalence of severe CKD was almost two-fold higher 
compared to non-Indigenous population.65,66 In Australia, research has shown that 
Indigenous people can be as much as 3-4 times more likely to have CKD than non-
Indigenous people.67 In native Australian communities, CKD may begin two or three 
decades earlier, without diagnosis; therefore, people who are diagnosed with CKD at 
middle age and have developed ESKD, essentially started developing CKD during their 
childhood.68 
In the last two decades, the prevalence of CKD among Indigenous populations in 
Canada has increased dramatically.69 In addition, the prevalence of CKD-related 
complications, such as ESKD, is 2 to 4 times higher when compared with non-Indigenous 
people.70,71  
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1.7 Adverse consequences of CKD 
CKD can lead to end stage kidney failure. In the last twenty years, the number of 
Canadians being treated for kidney failure has more than tripled. In Newfoundland, the 
rates for kidney replacement therapy (RRT) for kidney failure patients in 2013 were 
highest among all other provinces. Dialysis costs $56,000-107,000 per patient per year, 
meaning that the Canadian healthcare system expends around $2.5 billion annually for 
dialysis patients.72 
Both CKD and its treatment can take a great physical and psychological toll on 
individuals and families. Hemodialysis may take up to 5 hours a day and 3 times per 
week. On the other hand, although there are long waits and high initial costs, kidney 
transplantation may save the healthcare system over $250,000 per patient in dialysis 
costs over five years.73 
 
1.8 Kidney care delivery  
1.8.1 When should a patient be referred to a nephrologist?  
As the literature has shown, timely referral to a nephrology consultation delays 
CKD progression74, improves clinical outcomes75,76 and minimizes overall costs77. When 
there is no albuminuria present, the optimal time for this consultation occurs at CKD 
stage 3b when eGFR falls below 45 mL/min/1.73m2.37,78 Other important factors to 
consider in order to determine when a referral should be made include electrolyte 
imbalances, uncontrolled hypertension, metabolic abnormalities, urinary abnormalities, 
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and anemia.79 One quantifiable indication that may prompt the family physician to refer 
a patient for a nephrology consultation is a decline in the baseline eGFR at a rate equal 
to or greater than 5 mL/min/1.73m2 per year.80 A primary care provider might also seek 
an early nephrology consultation for those with diabetes and hypertension in patients 
showing any signs of hematuria, persistent proteinuria, or micro/macro-albuminuria in 
two consecutive urine tests at least 3 months apart.81 
A primary care provider can also enhance patients’ baseline knowledge of CKD 
with applicable CKD management guidelines and education.82 In patients with CKD and 
diabetes, management is mostly subject to a patient’s behaviors.83,84 Early intervention 
with high risk patients also means implementing patient-centered education for chronic 
disease management. Timely diagnosis of high-risk patients along with prompt 
intervention and patient-centered education not only slows the progression of CKD but 
also improves outcomes.85 
 
1.8.2 Stable and progressive CKD 
Kidney care accounts for a substantial amount of healthcare spending in 
Canada.86 To control the ever-increasing expense of kidney-care, researchers and policy 
makers have focused on the delivery of nephrology services as a way to regulate costs.87 
In Canada, over 2.9 million citizens have CKD at stage 3 or higher, meaning that their 
kidneys are functioning below or at approximately 60% of their normal capacity.50 
Among them, only a small number of patients are treated by nephrologists, with the 
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clear majority seen by a family physician in a primary care setting.88 Some of the CKD 
patients from both groups decline rapidly, their kidney function steeply deteriorates, 
and they need dialysis and/or a transplant in the end. However, in most cases, kidney 
function remains stable for years.89 Stable kidney function occurs when the level of 
eGFR decline is within the range of 1-4 ml/min/1.73m2 for 3 consecutive tests. This is 
opposed to progressive kidney function decline, which is referred to as 
>=5ml/min/1.73m2 decrease of eGFR per year.90 Physicians are often unable to 
recognize progressive kidney dysfunction, leading to late referrals and lost opportunities 
to slow kidney function decline.26,91 It is expected that kidney function will remain stable 
in patients who have stable kidney function irrespective of CKD stage and who are 
managed in a kidney care program. Their kidney function may not improve but it will 
usually not deteriorate either. On the other hand, with proper nephrology service 
delivery, it is possible to slow the rate of kidney function decline for some patients with 
a history of declining kidney function.92 For these patients, the regression of 
glomerulosclerosis may prolong the time before the onset of ESKD and its management 
and thus improve outcomes.93 
 
1.8.3 Early recognition and management of CKD  
A systematic approach to diagnosing CKD early is crucial. Simple blood and urine 
tests may identify most patients who are at an early stage of CKD. The National Kidney 
Foundation of America, through their Kidney Early Evaluation Program (KEEP), offers 
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free urine testing to all adult high-risk individuals with diabetes, HTN or family history of 
kidney failure to address kidney problems.94 Thus, just after detection, it is important to 
start renoprotective treatment immediately, not to cure CKD, but to slow down the 
deterioration of kidney function. This may also prevent complications arising from 
kidney disease, such as premature stroke or heart attacks, as well as progression to 
ESKD.3 By using both the administrative data and the health-related information with 
laboratory data, it has been shown that a simple urine test (the amount of protein in 
urine) is one of the most important predictors of the progression of chronic kidney 
disease.95 It is much easier to make informed choices about treatment options when 
CKD is detected early. And, if CKD progression is being well taken care of from its early 
stages, the prevention of ESKD is more likely.96  
 
1.8.4 Addressing the gaps 
The overall lifetime risks for CKD stage 3a (eGFR> 45 mL/min/1.73m2) from birth is 
estimated at 59%. The likelihood of more severe CKD is lower, for example the risk is 
3.6% for CKD stage 4 or more.97 So, recognition of CKD is vital, like recognition of 
diabetes and high blood pressure. Kidney function does decrease with age. Urine 
protein, which is a marker of kidney damage, needs to be on the list of lab tests for 
individuals who are at risk. People need to have a standard awareness of kidney disease 
parallel to the understanding of diabetes and hypertension that has existed for years.  
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Existing CKD awareness is low.98 Stage 4 CKD is present when kidney function is 
about one quarter of normal, yet only half of those who currently have severe kidney 
disease (CKD stage 4 or worse) are diagnosed. It is important to recognize what CKD is, 
detect it early, focus on the specialized treatment required, and reduce complications.99  
A study of CKD patients in Alberta determined that the chronic kidney disease 
clinical pathway (CKD-CP) online tool for primary care providers (PCP) greatly increases 
PCP’s ability to diagnose, manage and refer CKD patients and thus reduces evidence-
practice gaps in the primary care setting.100 
 
1.8.5 Kidney care service delivery in remote communities 
 In Canada, we have a health care system that triages people based on 
community to substandard care. There is a lack of access to kidney care services for 
people in remote areas which acts as a significant barrier to maintaining health.101 These 
barriers or challenges include but are not limited to healthcare professional shortage102, 
lack of access to kidney care103, long-distance travel to a kidney care facility104, and poor 
communication infrastructure for telehealth and e-consult105. The population in the 
remote communities face inadequate kidney care services compared to their 
counterpart living in close proximity to a health care facility. 
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1.8.6 Kidney care service delivery in Indigenous communities 
For the Indigenous population, especially for those living in remote locations, a 
major challenge is access to kidney care. Early diagnosis is important, but the distress 
involved with leaving the community/reserve to receive appropriate kidney care must 
be considered.106 On top of the stress associated with traveling for medical care, they 
also have very limited access to proper kidney care, amid a much higher prevalence rate 
of CKD, and this therefore creates a burden on the available resources.107 When 
compared with the non-Indigenous population, the likelihood of kidney transplantation 
for Indigenous people is only about one-third (hazard ratio=0.34).71 
 
1.9 Patient oriented research (POR) 
Engaging, listening to, and involving patients as partners in the research process 
enhances the impact and quality of research in a variety of ways. It ranges from 
formulating novel research questions, to taking new and interesting directions based on 
patients’ vast and diverse experiences. Engaging patients in this way is becoming a core 
component of some medical research.108 Patient oriented research (POR) can be 
instrumental in creating a framework that allows researchers to share their vision, 
interest, and concerns about research with the broader community. Through POR, 
researchers can interact and reach out to the widest possible audience. Increased 
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awareness of societal needs is one among many potential benefits when researchers 
and patients work together and define research strategies for a specific project.109 
The provision of integrated care is one feature of healthcare systems. There are 
many varying definitions for integrated healthcare in the literature. Common elements 
include: being patient-oriented, continuous delivery of healthcare, including healthcare 
research, and coordination between services.110 Unfortunately, in many instances, 
limited patient oriented research within healthcare services leaves a gap in integrated 
healthcare. This gap leaves many patients unaware of available advanced kidney care, 
whilst healthcare professionals miss the opportunity to listen to patients’ voices on 
healthcare deficits.111 The research inquiries and objectives that are important to 
patient partners are very different than the ones that researchers think are important. 
Incorporating the patients’ voice in all aspects of research is a key motivating factor in 
any population-based epidemiological research. Patients can ask questions, and be a 
part of the study design; their engagement is not limited to study participation, but also 
to looking at the results, interpreting the findings, and coming out with the best possible 
ways to disseminate these findings. All this makes the patient population the core of 
patient oriented research.112 
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1.10 Research objectives 
a.    To determine the distribution of chronic kidney disease in the Newfoundland 
and Labrador health regions, and how this distribution varies in particular 
subgroups characterized by region of residence, age, sex, presence of diabetes, 
progression of kidney disease, and residence in communities with more 
Indigenous people. 
b.    To determine the current status of CKD referrals and follow-ups by 
nephrologists in the province and across regions, for the same subgroups.  
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Chapter 2: Methods 
 
2.1 Settings 
Newfoundland and Labrador centre for health information is a custodian for 
provincial health data. Provincial health information standards for demographic, 
administrative, and clinical data are set by the Provincial Health Information 
Management Leadership Committee. The purpose of this standard is to ensure accurate 
and complete demographic and administrative information, a fundamental for valid and 
accurate patient identification. The information is collected within health care services 
at the point of patient registration/admission through standardized registration 
processes. Medical information technology (MediTech), the Client and Referral 
Management System (CRMS), Medical Care Plan (MCP), Vital Statistics, the Pharmacy 
Network, and Med Access (the provincial EMR) are among the registration modules 
from where the information flows into the provincial Client Registry for use by health 
care providers and other stakeholders, i.e. researchers. NLCHI maintains the Client 
Registry, which contains data including demographic information (name, address, date 
of birth) and administrative information (date of birth registration, MCP number, etc.). It 
allows accurate individual identifications by linking person-specific information from 
clinical information systems to the correct person. For laboratory specimens (e.g., 
blood/urine sample), laboratory staff enter lab results into MediTech while ensuring 
accuracy.113 
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Health data are being increasingly used in Canada.114 Although privacy is a major 
concern while disclosing public health information for secondary use, there is a growing 
demand for health data for public health research, and policy-making purposes.115 For 
that, high-quality data not only plays a vital role in providing objective information for 
study analysis but also helps in sound public health decision making. According to the 
University of Victoria eHealth observatory’s electronic medical records data quality 
evaluation guide116, a key characteristic of quality data is whether the data capture the 
same set of names for the same set of analytical variables. In NL, different health 
regions enter kidney function data by using different names for eGFR. Such 
inconsistency in kidney function test-results may impact clinicians’ ability to recognize 
and compare test results in a shared care situation. It may also affect practice reflection, 
an essential element for quality data, where health data is used. To negate such impact, 
NLCHI provided practical approaches to maintain the quality of data by identifying 
different eGFR test names (for example: EGFRCALC, EGFRC, GFRPMDRD, etc.).  
This retrospective cohort study was constructed by extracting records from the 
following data sets: the Medical Care Plan (MCP) database, the MediTech Laboratory 
database, the NLCHI Diabetes Database, the Canadian Organ Replacement Registry 
(CORR), NLCHI’s Out-of-Province Discharge Abstract Database (PDAD), the Canadian 
Socio-economic Information Management System (CANSIM) database, and the 
CanMap® Six Digit Postal Code v7.2 database. 
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For the purposes of determining CKD prevalence and to see where and when 
specialist care was received, linkage had been made at NLCHI between the MCP claims 
database for nephrologists in NL and the Meditech Laboratory Database. The Diabetic 
registry data set was used to identify all patients with diabetes and the proportion of 
these patients that has been tested for CKD. CKD patients who were on dialysis or have 
had a kidney transplantation were identified and excluded by using the CORR data and 
PDAD, respectively. 
In this chapter, the sources of the individual datasets used are reported, the 
characteristics of the variables used to analyze the data are discussed, and the methods 
used to analyze the data to address the study objectives are illustrated.   
 
2.1.1 MediTech laboratory data  
This includes records extracted from Regional Integrated Health Authority’s 
(RIHA) MediTech Systems’ Laboratory modules. Extracts were provided to NLCHI by 
each RIHA and include administrative, demographic and clinical information related to 
the laboratory tests performed in provincial facilities. The data (N=40,465 individuals) 
were used to identify all adult (18 years of age) chronic kidney disease (CKD) cases. 
Cases were identified by the study operational definition as individuals with CKD by an 
estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2 on at least two 
occasions, at least 3 months apart117, at some point of the study period between April 
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1, 2011 and December 31, 2015. [Please note – Laboratory data from January 1, 2011-
March 31, 2011 was not available due to quality issues identified by NLCHI Health 
Analytics and Evaluation Services Department during extraction].  
While albuminuria is a key feature that can also identify and grade CKD, this was 
not used in our study as a minority of cases had urine albumin measured. 
Characteristics of the variables from this database that are used in the study are 
described below. 
Patients’ study ID: A study code unique identifier is tabulated for each patient, 
named the ‘Study ID’. This allows the data to be de-identified for the analysis. 
Age: (NLCHI-derived): Age was determined to be incorrect in the source data 
(MediTech Laboratory Data) in the data validation process. The age information 
file was thus replaced with age-derived from the 2016 MCP Beneficiary Registry 
information (see section 2.1.2) to maintain the integrity and validity of data. 
Derived-Age in years was calculated based on the simple subtraction of the 
patients’ birth year from the laboratory test date. 
Gender: Male and female. 
Kidney function test: Each health region/facility utilized different names for the 
same or similar tests for kidney function. In the original data, both serum 
creatinine (SCr) and estimated glomerular filtration rate (eGFR) tests were 
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provided. Serum creatinine test results were later transformed into eGFR by 
using the Modification of Diet in Kidney Disease (MDRD) formula described 
earlier.31 CKD measured by eGFRMDRD with the clinically relevant cutoff values 
between 5-120 ml/min/1.73m2 was considered and any patients with eGFR 
below 5 ml/min/1.73m2 or above 120 ml/min/1.73m2 were eliminated from the 
data. 
Not every eGFR from the same patient was below 60 ml/min/1.73m2 
either before or after the period when they were identified. This is the working 
definition of CKD based on how it is applied by the NLCHI data analyst. The CKD 
is recognizable once the eGFR is below 60 ml/min/1.73m2 and stays there for 
three months, but this does not require that a physician has diagnosed the 
patient as having CKD. Therefore, some eGFRs appeared to be high and others 
appeared low within the study period. A choice has been made to cut-off the 
data when the eGFR were much too high or much too low to be clinically 
believable. This is because it is unlikely that these values represent a correct 
eGFR value. 
Values of eGFRs >120 ml/min/1.73m2 are not plausible values. This 
means that there must be something erroneous either in the data, or in the 
creatinine assay. Heavily built patients in general may have a high eGFR, but this 
does not make medical sense where there is an eGFR over 120 ml/min/1.73m2. 
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And moreover, the study focuses on people with CKD where an eGFR over 120 
ml/min/1.73m2 was really not relevant. For this reason, eGFR values over 120 
ml/min/1.73m2 were left out from the analysis. 
Very low eGFRs (<5 ml/min/1.73m2) were also left out. However, the 
study may include some dialysis patients, who are not registered with CORR, or 
patients who did have a very low eGFR at some point for various reasons such as 
acute kidney injury, for example. And again, the study focuses only on CKD 
patients, not dialysis patients. 
History of diabetes mellitus: Derived variable- based on linkage to NLCHI 
Diabetes Registry- indicates presence of patient records/information on diabetes 
in the Provincial Diabetes Registry. Patients with ‘Yes’ indicates the presence of 
diabetes and ‘No’, indicates the absence of diabetes. 
To be considered a diabetes case in the Provincial Chronic Disease 
Registry, an individual must meet the following criteria: 
 Identified as a diabetes case in the Canadian Chronic Disease 
Surveillance System (CCDSS): The diabetes case definition used by the 
CCDSS is one hospitalization or two or more physician visits with a 
diabetes diagnosis code (250 in ICD-9; E10-E14 in ICD-10) within a 2-
year period. While identifying individuals for diabetes from primary 
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care charts, this case definition has shown 86% sensitivity and 98% 
specificity.118 
OR, 
 Any two of the following test results in a two-year period: 
o Fasting Plasma Glucose test result of ≥ 7mmol/L, OR 
o Hemoglobin A1C test results of ≥ 6.5%, OR 
o 2-hour Plasma Glucose in a 75g Oral Glucose Tolerance Test 
result of ≥ 11.1 mmol/L, OR 
o Random Plasma Glucose test result of ≥ 11.1 mmol/L. 
Date of laboratory tests: Laboratory test dates were entered based on the 
Meditech Collection date for every test throughout the study period from April, 
2011, to December, 2015. 
Postal code information: Geographic information was based on six-digit postal 
codes taken from the 2016 MCP Beneficiary files (see section 2.1.2). The postal 
code indicates the patients’ place of residence in 2016.  
 
2.1.2  MCP fee-for-service physician claims data 
The MCP is an overall medical care insurance plan intended to cover the 
physicians’ service fee. The master database from the provincial MCP program of the 
Department of Health and Community Services is the primary source for MCP data. This 
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Registry based data is managed by NLCHI and consists of clinical, administrative and 
demographic information on patients’ eligibility for provincial MCP services. The data 
has 3 different files, namely the beneficiary registry, provider registry, and fee-for-
service (FFS) physician claims. The population size was 8,850 individuals in this database. 
The MCP Beneficiary Registry includes demographic information about 
individuals insured by the program and is a ‘snapshot’ of registrants’ information at a 
point in time, usually December 31 of a particular year. The person-specific health care 
number issued at the time of registration is also included.  
The Provider Registry includes demographic and licensing information about 
physicians registered to submit claims for services under the Newfoundland Medical 
Care Insurance Act. A unique identifier is provided to registrants for billing purposes. 
The Fee-for-Service (FFS) Physician Claims dataset includes clinical and other 
information about services claimed under the Newfoundland Medical Care Insurance 
Act. Date of service, place of service, and diagnostic and fee codes used to describe 
procedures/services performed are included. 
Patients who were residing as a permanent resident outside Newfoundland and 
Labrador were excluded. Residence outside NL was determined using MCP registry 
information.  
The medical licensing body is inconsistent in who they label as nephrologists. 
Part of this is historical – some were in practice before the Royal College recognized the 
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subspecialty. Some more recent ones may have been certified in the US and listed as a 
nephrologist by Credentials committees in the RIHAs. We invited all practicing 
nephrologists in NL seeking permission to use their visit data for the study [see 
Appendix A]. There were transiently also other nephrologists, who saw some 
nephrology cases but a lot of non-nephrology cases, so we left them out from the study. 
In terms of which physician visits we wanted to capture, this would essentially be visits 
to physicians who practice Nephrology. This excluded visits to internists per se even 
though a couple of those were listed as “Nephrologists” by the College, they were not 
credentialed to provide nephrology care. There are internists at Grand Falls who do 
provide dialysis, but they don’t do pre-dialysis CKD care which is the focus of this study, 
so their visits were not captured either. Eight nephrologists are practicing based on the 
city of St. John’s in ERIHA and two nephrologists are practicing in Corner Brook in 
WRIHA. A couple of nephrologists from ERIHA travel periodically to CRIHA and LG-RIHA. 
The following is the list of variables from this database that were analyzed.  
Patients’ Study ID: The same unique identifier as that of the MediTech 
laboratory data was used for CKD patients who had been seen by nephrologists. 
Nephrologist Visits: This was a derived variable based on the linkage with MCP 
FFS physician claims data. The variable denoted the count of visits with a 
nephrologist per CKD patient. All nephrologist visits throughout the study 
periods were taken into account. All nephrologists are fee-for-service and submit 
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claims. After the study period started, the first nephrologist visit was identified 
and then all subsequent visits were counted. 
Nephrologist Visit Date: Based on all service dates of nephrologist visits per CKD 
patient throughout the study period. 
Nephrologist Visit Location: RIHA location of nephrology service was recorded 
based on the most recent date of nephrologist visit. 
Postal Code information: The six digit postal code of CKD patients’ place of 
residence was extracted from the MCP Beneficiary file. 
 
2.1.3 The NLCHI diabetes database 
The database includes records for all residents of Newfoundland and Labrador 
who have been diagnosed with diabetes as recorded in provincial clinical information 
systems. The NLCHI Diabetes Database was used to identify all prevalent cases of 
diabetes between January 1, 2011 and December 31, 2015. Patients with ‘Yes’ indicates 
the presence of diabetes and ‘No’, the absence of diabetes. The presence/absence 
(Yes/No) of micro-albumin urine test (MALU) was provided. It was used to detect kidney 
damage in diabetic individuals who are at risk of developing CKD. The population size on 
this database was 76,692 individuals. 
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2.1.4 The Canadian Organ Replacement Registry (CORR) and NLCHI’s Out-of-Province 
Discharge Abstract Database (PDAD)  
CORR collects data from hospital dialysis programs, regional transplant 
programs, organ procurement organizations, and kidney dialysis services offered at 
independent health facilities. Patients are tracked from their first treatment for end-
stage organ failure (dialysis or transplantation) to their death, unless they are lost to 
follow-up. CORR data were linked at NLCHI and used to exclude patients on dialysis. 
Patients with ‘Yes’ indicated for Peritoneal/Hemodialysis were identified as dialysis 
patients and were excluded. Patients who have dialysis for acute kidney injury are not 
captured by the CORR data, and as such may have been included in the cohort. 
With respect to the transplant data, all NL kidney transplants were performed 
out of province (most were performed in Nova Scotia). The data submitted to CIHI were 
considered to be under the custodianship of the submitting province.  Therefore, 
CORR provided no transplant data. Patients who had a kidney transplant were therefore 
identified and excluded using NLCHI’s Out-of-Province Discharge Abstract Database.  
 
2.1.5 Canadian Socio-economic Information Management System database:  
(see Appendix B) 
Canadian socio-economic information management system is Statistics Canada's 
main socioeconomic time-series population database consisting of the number of 
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people living in a health region by age and sex. NL health regions are based on 
administrative boundaries defined by the provincial ministry of health according to 
provincial legislation. CANSIM was used for computing age-standardized and age and 
sex-specific CKD prevalence rates in different NL health regions from 2011 to 2015.119 
 
2.1.6  The CanMap® Six Digit Postal Code v7.2 database  
In order to effectively map each study ID’s location to each health authority, six digit 
postal codes were used. The CanMap® 6 digit postal code database contains the most 
precision-based points representing addresses across Canada. The database is produced 
by DMTI Spatial, a Digital Map Products company (a private company that creates the 
CanMAP geographic information system (GIS) Data used by the federal 
government/universities). The CanMap file also includes the Canada Directory which 
contains provincial boundaries, regional municipality boundaries, area code boundaries, 
and the 1996 census subdivisions (CSD) boundary data. The postal codes are 
subsequently mapped to regional municipality boundaries (communities) and then 
regional health authorities. Finally, latitude and longitude coordinate points were used 
to locate different communities on the map.   
Data for study cases were arranged in an SPSS data file and then imported to the 
GIS-based mapping software, ‘Tableau’. Specific communities belonging to their 
Individual cases were represented on the map, according to their postal code 
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information. The coordinate (latitude and longitude) locations of the communities of the 
CKD population were derived from the postal codes provided for each patient in the 
Meditech Laboratory and the MCP Fee-for Service Physician Claims databases. 
Coordinates that were not recognized by the CanMap® Six Digit Postal Code v7.2 
database were manually inserted into the Tableau software after online Google search 
of the postal code specific to the community. The display of communities on the map 
was then pointed out by dots. 
To ensure that the privacy of the patients included in this study was not 
compromised as a result of analyzing the 6 digit postal code data, the rule of five 
method was used to prevent any re-identification of patients through spatial 
information. Any sub-region or aggregate that had less than five patients was merged 
with an adjacent sub-region or aggregate so that none of the areas being analyzed had 
less than five patients. This process is widely used as a method to prevent the re-
identification of patients through spatially referenced data. 
 
2.2 Study design 
This is a retrospective cohort study to establish CKD prevalence and to 
understand kidney care delivery service across different health regions of NL. This study 
also utilizes the GIS mapping that helped visualization of people living in the remote 
communities with the burden of CKD.  
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We were able to look at the number of people in the broader municipal 
communities within each health region. For reasons of privacy and confidentiality, we 
could not identify people in very small communities. It is NLCHI policy not to identify 
individuals within groups of smaller than 5 people with CKD. Since we cannot analyze 
the very small communities because of the limitations of the policy, we choose bigger 
sites of CKD population (thirteen communities) for comparative analyses. The 
differences in the proportion with CKD between the larger communities (namely St. 
John’s region, Carbonear, Burin, Clarenville, Bonavista, Gander, Grand-Falls-Windsor, 
Corner Brook, Stephenville, Port-aux-Basques, St. Anthony, Happy Valley-Goose Bay, 
Labrador City) were compared. Four health regions were compared first in terms of the 
proportion with identifiable chronic kidney disease and then broken down within the 
regions into specific communities.  
 
2.3  Research team 
A multidisciplinary research team, with varying expertise and skill sets, was 
introduced because of the varying nature of the study. The research team consists of a 
master's student [Dr. Mohammad Akhtar Hossain] from the department of clinical 
epidemiology as a principal investigator, one professor of medicine (nephrology), Dr. 
Brendan Barrett, as a supervisor, two associate professors of medicine (nephrology), 
Drs. Sean Wilson Murphy and John Shik, as co-supervisors, and a research coordinator 
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[Oliver Hurley] from the faculty of medicine. The expertise of this research team 
included research design, data analysis, geographic information system analysis, kidney 
disease, and biostatistics. I was responsible for various stages of research design 
including but not limited to protocol writing, study design, data screening/cleaning, data 
analysis and report writing. I was further supported by three co-investigators (patients 
or related to patients: Ms. Kim Hickman, Ms. Carla Thompson and Ms. Trina Ralph) as 
part of the patient oriented research. 
 
2.4 Research environment 
This study was carried out within the Clinical Epidemiology Research Unit at the 
Memorial University of Newfoundland. It had the necessary infrastructure [e.g. 
adequate space, equipment (a desktop with the necessary software including Microsoft 
office and statistical package [International Business Machines- Statistical Package for 
the Social Sciences (IBM SPSS)], and facilities (i.e. conference space, projector etc.)], to 
conduct this research study, including access to the Memorial University of 
Newfoundland Health Science library for access to the current literature. 
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2.5 Study population, inclusion, and exclusion criteria 
All patients with identifiable chronic kidney disease (see operational CKD 
definition, page 37) at the various Newfoundland and Labrador health regions between 
April 1, 2011, and December 31, 2015, were included in the study. 
 
2.5.1 Inclusion criteria  
Age ≥ 18 years 
Identified CKD patients based on laboratory criteria 
Diabetic patients aged ≥18 years 
2.5.2 Exclusion criteria  
Patients who were on chronic dialysis 
Patients who have had a kidney transplantation 
Patients who were residents outside Newfoundland and Labrador 
(NLCHI did not report the number of people excluded because of dialysis 
and transplantation) 
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2.6 Data analysis in the Indigenous population 
There was an interest from patient partners in looking at any differences 
between Indigenous and non-Indigenous people with CKD in Labrador-Grenfell Health 
region. We do not have data to assign the Indigenous status of individuals; as such, we 
are using the coastal community with majority Indigenous people as a proxy. These 
coastal communities with CKD (namely, Cartwright, Charlottetown-Labrador, Hopedale, 
Makkovik, Mary’s Harbour, Mud Lake, Nain, Natuashish, North West River, Port Hope 
Simpson, Postville, Rigolet, and St. Lewis) have a majority (>80%) Indigenous 
population.120 [Appendix C] Therefore, to determine whether or not there is a difference 
between Indigenous and non-Indigenous communities, we use these coastal 
communities as an approximation of an Indigenous population. Thus, the proportion of 
CKD patients within the Labrador coastline communities reflects the CKD prevalence in 
the Indigenous population rather than in the Caucasian population. We use this proxy 
measure as individuals are not identified as Indigenous or not in the dataset.  
 
2.7 Sample size calculation 
As all patients' records, available and documented in the NLCHI registry, were 
included in the study design for the selected study period of April 2011 to December 
2015, sample size calculation was not necessary to conduct this retrospective 
observational study. However, as our primary objective is to establish CKD prevalence, 
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we only need 3,457 CKD with 95% confidence interval based on the following formula of 
sample size calculation for prevalence study.121  
 
n = Z2 x P (1-P) / d2 
 
where,  
n = sample size,  
Z = 1.96; Z-statistic for a level of confidence, 
P = expected prevalence or proportion (in proportion of one; here, national CKD 
prevalence of 10% was used, P = 0.1), and 
d = precision (in proportion of one; in this case 1%, d = 0.01). 
 
Thus, a sample size of 3,457 would provide 95% confidence with 1% absolute error in 
the estimated prevalence of CKD among the NL population. We based our calculation 
here on knowing that we would have sufficient cases to identify the prevalence. 
 
2.8 Patients’ engagement 
 To facilitate the process of patient-oriented research, three patient partners 
were invited, by email notification [Appendix D], at different phases as the study moved 
forward. These phases include: a) inclusiveness: patient engagement was blended with 
patients’ perspectives, cultures, and their kidney care experiences; b) initial protocol 
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writing phase: we held a meeting with these patients, participants were asked to review 
the research proposal and for any new ideas to add or gather feedback on already 
existing information; c) research outcome phase: requested interpretation of results; d) 
knowledge translation phase: asked patients partners to help share the research 
outcomes. 
 
2.9 Data analysis 
Descriptive analyses were used to calculate the prevalence. The prevalence was 
reported as percentage (%). For descriptive purposes, patients’ kidney function 
measured by eGFR was categorized as such: <60 (45-59), <45 (30-44), <30 (15-29), and 
<15 (5-15) ml/min/1.73m2. Individuals were grouped into five age categories (18-39, 40-
49, 50-59, 60-69, and 70+ years) based on their age at baseline (2011).  
We determined CKD prevalence in a number of steps. First, we considered the 
proportion of CKD patients in different RIHA communities by age group for each year of 
the period 2011-15. Then, we looked at the proportion of the CKD population who were 
and were not seen by a nephrologist. We also examined the influence of factors (age, 
sex, diabetes, health region, CKD stages, and kidney function stability) on the frequency 
of nephrologist follow-ups. And finally, we documented CKD among the Indigenous 
communities. The following chart (Figure 2) shows all components of analysis followed 
in this study. 
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Figure 2: Study analytical approach. 
 
 Distribution of CKD across RIHA communities by age, 2011-15 
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 Association between nephrologist visit and patients’ demographics and clinical 
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 Kidney care delivery  
 Direct age-standardized rate for nephrologist visits  
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 Status of referral to a nephrologist for CKD patients 
 Proportion of CKD patients receiving nephrology service within their own 
region  
 Distribution of CKD in Indigenous community 
 Proportion of people with diabetes tested for CKD 
 Outcomes of patient engagement 
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The differences between how often a patient receives follow up services within 
different communities and health regions were measured by the frequency of 
laboratory tests and nephrologists’ visits. Frequent lab tests influence the likelihood of 
identifying CKD and also reflect the adequacy of care.122 Depending on the prior 
laboratory findings, it is important to look at differences in the frequency of blood work 
at varying degrees of kidney function for CKD patients. Also, to assess the degree to 
which current nephrology service delivery matches the apparent needs, the study 
compared follow up frequency for CKD patients by the number of nephrologist visits 
between the health regions and different communities as well.   
We used direct standardization to calculate age-adjusted and sex-specific CKD 
distributions among four health regions. Age-adjustment, also known 
as age standardization, is used to compare populations with variable age groups. 
To determine the age-adjusted rate, we first calculate the age-specific CKD rates for 
each age group by dividing the respective population CKD number, and multiply by 
1,000.123 Direct age-standardized and sex specific prevalence were calculated using 
Statistics Canada’s Canadian Socio-Economic Information Management System 
(CANSIM) table 109-5355.  
Kidney function stability was measured by the progression of CKD, a rate of 
kidney function decline per year. If kidney function drops at a rate of equal to or greater 
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than 5 ml/min/1.73m2 (measured by eGFRMDRD) per year, this is considered unstable or 
progressive chronic kidney disease.90  
We used a logistic regression model to evaluate the likelihood of an individual 
being seen by a nephrologist by patients’ demographics (age, sex, diabetes status, CKD 
stage and stability of kidney function).  
Logistic regression was applied since the dependent variable is dichotomous 
(either being seen by a nephrologist or not). The Odds ratio and 95% CI were calculated 
to assess the association of nephrologist visits by patients’ characteristics. A P value less 
than 0.05 was considered to indicate statistical significance. 
On clinical grounds, all of the following parameters are relevant potential 
predictors, and thus we decided to enter them all into the model at the same time. We 
did not perform stepwise addition or deletion. In developing a logistic model, we first 
decided which variables of the data to which we had access will be clinically relevant, 
and then, we used the enter method to force them all into the model at the same time 
to allow for multivariable adjustment. Omnibus test was used to compare the fitted 
model against the intercept-only model.  
The null hypothesis for the overall model fit: The overall model does not predict 
nephrologist visit; the independent variables as a group are not related to being seen by 
a nephrologist.  
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The alternative hypothesis for the overall model fit: The overall model predicts 
the likelihood of a nephrologist visit. Being younger (vs. older), male (vs. female), having 
diabetes (vs. not diabetic), living in different health regions, having unstable kidney 
function, and low average eGFR per year are related to the likelihood of being seen by a 
nephrologist. 
Using generalized linear models (GLMs), we assessed the association between 
the frequency of nephrology visits during the study period (the dependent variable), and 
independent variables (age, sex, diabetes status, eGFR, health region and kidney 
function stability). Unlike linear models in which the distribution of the dependent 
variable needs to be normally distributed, GLMs allow the dependent variable to be any 
member of an exponential family (e.g. binomial, Poisson, multinomial etc.).124 In this 
study, the dependent variable is the frequency of nephrologist visits, which is a count 
variable and also shows skewed distribution; hence, the Poisson regression analysis, 
under GLMs, was used. The GLM analysis was, thus, limited to those CKD patients who 
had at least one nephrology visit. Individuals without nephrologist visits were not 
included in this analysis. Adjusted odds ratios are presented to illustrate the association 
of nephrologist visit frequencies with independent variables. Comparisons between 
categories such as CKD stages were considered statistically significant with a p-value less 
than 0.05. Omnibus test for Poisson regression was used to compare the fitted model 
against the intercept-only model. 
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Missing information is only the values where the specific missing piece of data is 
needed to perform a particular analysis. For example, if postal code is missing for a 
patient with CKD, that person is not included in the geographic distribution analysis but 
is included in other analyses, such as the analysis of the frequency of nephrologist visits. 
The Statistical Package of Social Science (IBM SPSS Statistics for Windows, 
Version 22, Armonk, NY: IBM Corp.) was used to perform all statistical analyses.  
 
2.10 Ethical considerations 
2.10.1 Protection of Human Research Participants (PHRP)  
As the study involved the analysis of de-identified past records and did not have 
any direct contact with Human Research Participants (HRP), there were no physical or 
medical risks involved. The study protocol approval from the Provincial ethics review 
board was obtained (Researcher Portal File #: 20170288; study 2016.153) and the study 
was conducted in conformity with the Tri-Council Policy Statement (TCPS 2). 
 
2.10.2 Data safety, security, and confidentiality 
All due precautions as prescribed in the TCPS 2 were taken to safeguard the 
confidentiality of the information derived from the NLCHI data set. Each complete data 
file included only a study code unique identifier (Study ID) ensuring that any patient 
identifier was removed by NLCHI staff before the data was made available for analysis. 
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The data regarding linkages between the study data set and the original data set was 
kept in the custody of NLCHI. The data was linked first and then de-identified by NLCHI, 
who then sent it to the Center for Health Informatics and Analytics (CHIA) at MUN. 
 
2.10.3 Data retention and disposal after the retention period 
Any hard copies of data were kept in a locked cabinet at CHIA with Mitch Sturge 
(Associate Director, CHIA room # 4M419; 709.864.6440; mitch.sturge@med.mun.ca) 
Once the project was completed, research data was secured and will be kept for 
5 years. At the end of the data retention period, all data will be securely removed by a 
thorough data removal procedure according to the MUN data retention and disposal 
policy. Stored data will be erased by using multiple passes of data wiping software to 
ensure that the data will not be retrievable using recovery methods.  
 
2.11 Funding sources 
This project was funded by a Translational and Personalized Medicine Initiative 
(TPMI)/NL SUPPORT Educational grant. All funding was administered through the Office 
of Research & Graduate Studies, the Faculty of Medicine and University Finance Office. 
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Chapter 3: Results 
 
Considering the 438 communities that the CKD patients reside in, a total of all 
40,465 patients were taken into account in this study. Of them, 188 communities were 
from the Eastern RIHA followed by 135, 69, and 46 communities from the Central RIHA, 
Western RIHA and Labrador-Grenfell RIHA, respectively. The distribution of these 
communities is shown in the map (Figure 3 and 4). Among these communities, the 
larger communities were St. John’s (CKD, N=9,457), Carbonear (657), Burin (198), 
Clarenville (1,070) and Bonavista (670) from the ERIHA (29,457); Gander (355) and 
Grand-Falls-Windsor (483) from the CRIHA (3,354); Corner Brook (2,126), Stephenville 
(500), and Port-aux-Basques (509) from the WRIHA (6,237); and St. Anthony (181), 
Happy Valley-Goose Bay (140), and Labrador City (79) from the Labrador-Grenfell 
(1,239) Health authority. 
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Figure 3: Distribution of CKD communities in Newfoundland and Labrador. 
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Figure 4: Number of CKD cases across communities in Newfoundland and Labrador.
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3.1 Baseline characteristics  
 The numbers of identified CKD people within each of the variables of interest are 
presented in Table 1. 
Table 1: Baseline characteristics of the study population 
Variables Number of CKD 
patients (%) 
The number of people in the 
cohort 
40465 
  
Age (years) 
18-39 
40-49 
50-59 
60-69 
70+ 
Missing 
 
561 (1.4%) 
1,970 (4.9%) 
5,918 (14.6%) 
12,048 (29.8%) 
19,865 (49.1%) 
103 (0.2%) 
  
Male 15,948 (39.4%) 
  
Diabetes 16,663 (41.2%) 
  
RIHA 
ERIHA 
CRIHA 
WRIHA 
G-Labrador  
Missing 
 
 
29,457 (72.8%)  
3,354 (8.3%) 
6,237 (15.4%) 
1,239 (3.1%) 
178 (0.4%) 
  
Nephrologist Visit 8,550 (21.2%) 
 
*103 CKD individuals had no information about their age; 178 CKD did not have postal code information; 
eGFR= Estimated glomerular filtration rate; RIHA=Regional Integrated Health Authority; ERIHA=Eastern 
RIHA; CRIHA=Central RIHA; WRIHA=Western RIHA; G-Labrador=Labrador-Grenfell RIHA 
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3.2  Distribution of CKD by age across RIHA communities, 2011-15  
 
  When considering all years of the study, the proportion of CKD patients at 
different age groups varied widely across regions. In most communities, the highest CKD 
proportion were in the older age group, except in Labrador City, where the highest 
proportion was seen within the middle-aged population (36.7% in age 60-69 and 26.6% 
in age 50-59 vs. 24.1% in age 70+). Also, table 2 suggests that those aged 40-49 years in 
Labrador city were more likely to have CKD (10.1%) compared to those of the same age 
group in other communities (Table 2). 
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Table 2: Distribution of CKD across RIHA communities by age (2011-15) 
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18-39 1.4 1.4 1.4 1.5 2.2 1.0 2.3 1.7 1.0 0.4 1.2 0.6 1.4 1.3 
40-49 4.9 4.7 3.8 5.1 5.8 5.2 4.8 2.1 2.4 3.2 3.1 6.1 7.9 10.1 
50-59 14.6 13.1 12.2 16.2 14.4 15.4 10.1 9.7 11.1 13.6 10.2 11.0 15.7 26.6 
60-69 29.8 26.1 28.5 37.9 26.2 26.1 21.1 26.9 27.1 26.6 30.3 32.6 30.7 36.7 
70+ 49.1 54.5 54.0 39.4 51.2 51.8 61.4 59.2 58.0 55.8 55.0 49.7 43.6 24.1 
*N=number of population (as denominator); RIHA=Regional Integrated Health Authority; numbers are presented as %; census 2011 
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3.3  Distribution of CKD by RIHA communities by stage 
The proportions of CKD population, within each CKD stage, showed a fairly 
consistent rise for the first four years and then fall in last year of the study period. This is 
possibly due to the method used to identify CKD which requires two measurements 
below a cutoff at least three months apart. Some people who truly have CKD would 
have a single final creatinine in 2011 while others would have a single first creatinine in 
2015. Both were excluded from the original data due to their not meeting the case 
definition. This would artefactually affect the prevalence and the pattern we see. For 
this reason, we chose the year 2013 to comment on comparisons across communities.  
Among CKD patients in 2013, Bonavista (11.75%) showed the highest prevalence 
of mild to moderate kidney dysfunction (eGFRMDRD: 45-59 ml/min/1.73m2), followed by 
Clarenville (10.67%) and Carbonear (9.45%) from the ERIHA. Channel Port-Aux-Basque 
from the WRIHA exhibited a 7.65% prevalence rate of mild to moderate kidney 
dysfunction while St. Anthony from LGRIHA showed a rate of 5.00% in 2013. Prevalence 
rates of moderate to severe CKD (<45 ml/min/1.73m2), severe CKD (<30), and end stage 
kidney disease (<15), were highest in Bonavista (5.16%, 1.39%, and 0.09%, respectively) 
(Table 3). 
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Table 3: Distribution of CKD RIHA communities by level of eGFR (2011-15) 
 RIHA  Eastern Central Western Labrador-Grenfell 
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eGFR <60 2011 3.44 3.89 6.06 3.34 7.36 8.58 1.31 1.44 6.24 3.91 6.71 4.05 0.69 0.32 
 2012 4.04 4.63 7.73 4.08 8.08 9.45 1.69 1.83 6.30 4.44 6.71 4.51 0.86 0.41 
 2013 4.89 5.65 9.45 4.91 10.67 11.75 1.75 1.81 7.50 5.39 7.65 5.00 1.09 0.50 
 2014 5.18 5.73 9.98 5.49 11.64 12.53 1.36 1.91 7.96 5.58 9.26 6.29 1.46 0.65 
 2015 4.30 4.60 9.82 5.24 9.90 11.54 1.45 1.83 4.58 2.99 4.96 6.37 1.21 0.56 
                
eGFR <45 2011 1.21 1.31 2.36 1.36 2.34 3.48 0.53 0.75 2.14 1.46 2.54 1.74 0.21 0.13 
 2012 1.41 1.54 3.16 1.94 2.64 4.15 0.69 0.92 2.12 1.70 2.49 1.82 0.33 0.14 
 2013 1.68 1.84 3.53 1.94 3.13 5.16 0.78 0.99 2.75 2.08 3.21 2.23 0.41 0.20 
 2014 1.78 1.85 3.66 1.98 3.48 5.10 0.62 0.98 2.91 2.23 3.41 2.52 0.53 0.27 
 2015 1.54 1.50 3.78 1.77 3.12 4.50 0.67 0.95 1.96 1.41 2.09 2.73 0.49 0.20 
                
eGFR <30 2011 0.27 0.26 0.39 0.37 0.70 0.75 0.15 0.26 0.41 0.39 0.50 0.33 0.00 0.02 
 2012 0.33 0.34 0.62 0.45 0.79 0.90 0.21 0.33 0.40 0.37 0.72 0.45 0.02 0.04 
 2013 0.40 0.41 0.74 0.41 0.75 1.39 0.24 0.28 0.60 0.48 0.89 0.41 0.07 0.02 
 2014 0.43 0.40 0.97 0.50 0.78 1.42 0.21 0.30 0.64 0.45 0.96 0.70 0.09 0.05 
 2015 0.39 0.34 0.93 0.50 0.75 1.39 0.25 0.34 0.47 0.33 0.53 0.91 0.11 0.05 
                
eGFR <15 2011 0.01 0.01 0.00 0.00 0.02 0.00 0.01 0.04 0.01 0.03 0.00 0.00 0.00 0.00 
 2012 0.02 0.02 0.00 0.00 0.03 0.03 0.01 0.03 0.03 0.01 0.02 0.00 0.00 0.00 
 2013 0.03 0.03 0.02 0.00 0.06 0.09 0.02 0.04 0.03 0.03 0.02 0.00 0.00 0.00 
 2014 0.04 0.03 0.04 0.00 0.05 0.12 0.02 0.04 0.05 0.06 0.02 0.04 0.00 0.00 
 2015 0.04 0.04 0.06 0.08 0.10 0.20 0.01 0.04 0.06 0.01 0.02 0.17 0.00 0.02 
*N=number of population (as denominator); RIHA=Regional Integrated Health Authority; eGFR=estimated glomerular filtration rate 
(ml/min/1.73m2); all numbers are presented as %.
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3.4  Distribution of CKD in NL by stage in relation to age, sex, and diabetes status 
 
In NL, moderate to severely decreased kidney function (eGFR <45, <30 and <15 
ml/min/1.73m2) patients were mostly in the older (70+ years) age group, more likely to 
be female, and more likely to have diabetes. However, the majority (54.6%, 57.6%, and 
57.9%) of mild to moderate CKD (eGFR <60 ml/min/1.73m2) patients were below 70 
years of age and did not have diabetes mellitus during 2013, 2014, and 2015 
respectively (Table 4). 
The proportion of 70+ years individuals with CKD dropped in each stage over 
every year considered by the study. The proportions of those with CKD under 70 years 
of age tended to remain stable or increase in each stage over the study’s time-period.  
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Table 4: Distribution of CKD by level of eGFR, time (2011-15), age, sex and diabetes status 
 
  Age Groups (years) Gender Diabetes status 
 Year 18-39 40-49 50-59 60-69 70+ Male Female Yes No 
*eGFR <60 2011 0.7 3.6 12.4 29.8 53.2 39.3 60.7 42.6 57.4 
 2012 0.9 3.5 13.3 30.8 51.2 39.1 60.9 40.4 59.6 
 2013 1.1 4.6 15.3 33.3 45.4 39.2 60.8 37.6 62.4 
 2014 1.2 5.1 16.6 34.4 42.4 39.3 60.7 36.1 63.9 
 2015 1.1 5.2 16.6 34.8 42.1 39.1 60.9 37.3 62.7 
           
eGFR <45 2011 0.5 1.7 6.4 19.8 71.4 37.7 62.3 52.9 47.1 
 2012 0.6 2.0 6.5 19.9 70.8 37.1 62.9 51.3 48.7 
 2013 0.6 2.1 7.2 21.8 68.0 37.1 62.9 50.8 49.2 
 2014 0.7 2.3 8.0 24.1 64.6 37.1 62.9 51.1 48.9 
 2015 0.7 2.4 8.6 25.4 62.6 38.9 61.1 50.9 49.1 
           
eGFR <30 2011 1.0 1.6 6.0 12.7 78.6 35.4 64.6 57.9 42.1 
 2012 0.6 1.8 5.8 14.5 77.0 37.0 63.0 57.8 42.2 
 2013 0.8 2.1 5.7 15.4 75.7 36.0 64.0 57.3 42.7 
 2014 0.8 2.3 7.3 17.4 71.9 37.0 63.0 57.8 42.2 
 2015 0.8 2.8 7.7 19.4 69.0 38.5 61.5 58.9 41.1 
           
eGFR <15 2011 0.00 2.90 2.90 13.04 81.16 30.43 69.57 55.07 44.93 
 2012 0.00 3.74 8.41 14.02 73.83 23.36 76.64 57.01 42.99 
 2013 0.72 2.17 10.14 13.77 73.19 34.78 65.22 62.32 37.68 
 2014 1.54 4.62 9.23 16.92 67.18 31.28 68.72 57.44 42.56 
 2015 3.03 4.76 9.96 21.65 60.17 36.80 63.20 60.17 39.83 
*eGFR=estimated glomerular filtration rate measured in ml/min/1.73m2; all numbers are presented as %; Number of populations in 
NL=528,448 (as denominator)
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3.5  Frequency of eGFR measurements  
 
Similarities were noted in the average frequency of kidney function tests (eGFR) 
for CKD patients among communities over the study period, but the averages were not 
identical (Table 5 and 6). In 2011, the range of average eGFR test frequency was 
between 3 and 5 tests per year. Test counts jumped to 9 tests per year in some 
communities (Carbonear, 9.60.7 and St. Anthony, 9.30.8) in 2015.  
For communities in the Eastern Health Region, eGFR test-counts have hovered in 
the range of 7-9 tests per year for the past few years. However, eGFR test counts have 
decreased in some Western Health Region communities (for example, in Corner Brook, 
the average test-counts were 7.50.2 in 2014 and 3.50.1 in 2015).  
Communities from the Central Health Region showed a steady eGFR test-count 
of 3.4 to 4.1 tests per year for five consecutive years from 2011 to 2015. eGFR test 
count for coastal Indigenous communities increased in last two years (7.90.7 in 2014 
and 7.00.8 in 2015) compared to the previous years (3.40.4 in 2011, 4.90.5 in 2012, 
and 4.40.3 in 2013).  
Variations in eGFR test frequencies between age groups can be seen in Table 6. 
Two age groups (young adult, 18-39 years, and elderly, 70+ years) have a higher 
frequency of eGFR tests compared to the middle age groups. An even greater variation 
was observed between diabetic and non-diabetic CKD patients across the province (such 
56 
 
as, 8.33.7 eGFR tests for diabetic patients in 2013, compared to 6.12.7 eGFR tests for 
non-diabetic patients). The frequency of eGFR tests for female CKD patients was slightly 
lower throughout the study period than for male patients (i.e., in 2013, the eGFR test-
count frequency was 7.34.7 for males vs 6.84.4 for females). 
57 
 
Table 5: Frequency of CKD eGFR testing across RIHAs and communities (2011-15) 
 eGFR test frequency (Mean+SE) each year 
 2011 2012 2013 2014 2015 
Overall, NL (N=40465) 4.70.0 6.20.0 70.1 7.40.1 6.90.1 
ERIHA (N=29457) 50.1 6.50.1 7.40.1 7.80.1 7.50.1 
CRIHA (N=3354) 3.40.1 4.10.1 4.10.1 3.90.1 3.40.1 
WRIHA (N=6237) 4.50.1 5.90.1 6.80.1 7.10.1 3.50.1 
G-Labrador (N=1239) 3.10.2 4.20.2 4.90.2 6.80.3 7.70.3 
      
ERIHA (N=29457):      
St. John's (N=9457) 5.30.1 7.00.1 7.70.1 7.70.1 7.50.1 
Carbonear (N=657) 4.10.3 5.50.5 6.80.4 8.30.4 9.60.7 
Burin (N=198) 5.90.5 6.80.6 8.60.8 9.61.0 8.90.6 
Clarenville (N=1070) 4.50.2 5.80.2 6.60.2 7.80.3 7.10.2 
Bonavista (N=670) 5.70.2 7.20.4 8.30.4 9.20.4 7.90.3 
      
CRIHA (N=3354):      
Gander (N=355) 3.20.2 3.90.3 3.80.3 3.60.3 3.50.4 
Grand Falls Windsor (N=483) 3.30.2 3.90.2 3.90.2 3.80.4 3.50.2 
      
WRIHA (N=6237):      
Corner Brook (N=2126) 4.70.1 6.10.2 7.10.2 7.50.2 3.50.1 
Stephenville (N=500) 4.50.2 5.70.4 6.20.4 6.30.3 3.30.2 
Channel Port Aux Basques (N=509) 4.10.2 5.30.3 6.80.4 6.80.3 3.70.2 
      
G-Labrador (N=1239):      
St. Anthony (N=181) 2.60.2 4.40.7 5.70.9 7.20.7 9.30.8 
Happy Valley-Goose Bay (N=140) 3.60.4 5.10.5 6.20.8 8.90.9 5.60.7 
Labrador City (N=79) 3.80.5 4.90.6 5.40.6 7.71.2 4.90.7 
Indigenous Coastal communities (N=133) 3.40.4 4.90.5 4.40.3 7.90.7 7.00.8 
*eGFR=estimated glomerular filtration rate measured in ml/min/1.73m2; SE=standard error; N=number of CKD (as denominator); 
RIHA=Regional Integrated Health Authority; ERIHA=Eastern RIHA; CRIHA=Central RIHA; WRIHA=Western RIHA;  
G-Labrador=Labrador-Grenfell RIHA
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Table 6: Frequency of CKD eGFR testing in NL by Age, sex and diabetes status (2011-15) 
 
 eGFR test frequency (Mean+SE) each year 
NL (N=40465) 2011 2012 2013 2014 2015 
Age (years), 18-39 4.63.3 5.74.4 7.55.2 8.33.9 7.43.1 
40-49 4.13.9 5.75.8 6.75.9 6.12.9 6.32.8 
50-59 4.34.2 5.55.4 6.44.4 6.93.1 6.52.6 
60-69 4.33.9 5.64.9 6.74.5 7.13.2 6.62.5 
70+ 5.24.3 6.75.5 7.44.3 7.83.3 7.22.3 
      
Sex, Male 4.94.3 6.55.6 7.34.7 7.83.4 7.32.6 
Female 4.64.1 5.95.1 6.84.4 7.13.1 6.62.4 
      
Diabetes status, Yes 5.53.2 7.44.3 8.33.7 8.82.8 8.21.9 
No 4.12.4 5.33.1 6.12.7 6.42.0 5.91.4 
*eGFR=estimated glomerular filtration rate measured in ml/min/1.73m2; SE=standard error; N=number of CKD (as denominator); 
RIHA=Regional Integrated Health Authority; ERIHA=Eastern RIHA; CRIHA=Central RIHA; WRIHA=Western RIHA;  
G-Labrador=Labrador-Grenfell RIHA
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3.6  Nephrology visits across patients’ demographics and clinical characteristics  
 
Eight thousand, eight hundred fifty CKD patients who had seen a nephrologist, 
and 31,615 patients who were not seen by a nephrologist at any time during the 5-year 
study period (2011-2015), were taken into consideration for comparison purposes. 
(Table 7) The mean age of CKD patients without nephrologist visits was 68.9±12.0 years, 
compared to the mean age of those who had at least one nephrologist visit, which was 
68.3±12.5 years. The highest proportion of younger CKD patients who were seen by a 
nephrologist was exhibited in WRIHA (59.6%), compared to the ERIHA, CRHIA and 
Labrador-Grenfell health regions (28.5%, 35.1%, and 50.0%, respectively). Overall, in 
Newfoundland, only 32.3% of CKD patients aged 18-39 years saw a nephrologist. In 
WRIHA, CKD patients are more likely to see a nephrologist, but a lot of people are still 
not being seen. In NL, 21.5% of 70+ age CKD patients are actually seen, while 46.4% are 
seen in WRIHA. Nephrologists in WRIHA are seeing almost half of the people over 70 
years old with CKD. This is a high proportion compared to anywhere else. 
Among males with identifiable CKD, 46.9% were seen by a nephrologist in 
WRIHA, compared to 19%, 22.5%, and 30.3% in ERIHA, CRIHA, and Labrador-Grenfell 
health regions, respectively. Interestingly, the proportions of male CKD patients seen by 
a nephrologist are higher than the proportion of female CKD patients seen by a 
nephrologist in all four health regions.  
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As expected the diabetic patients with CKD are more likely to be seen by a 
nephrologist compared to non-diabetic patients with CKD. Again, the highest proportion 
of diabetic patients with CKD who were seen by a nephrologist was seen in WRIHA 
(48%), compared to the other health regions (21.5%, 22.4%, and 28.1% in ERIHA, CRIHA, 
and Labrador-Grenfell, respectively). 
In general, when we look according to the eGFR levels, the bulk of those who 
have really bad kidney function get seen by a nephrologist, but very few people with 
more preserved kidney function get seen. Specifically, in WRIHA and Labrador-Grenfell, 
all identifiable CKD patients who are at stage 5 were seen by a nephrologist compared 
to those in ERIHA (80.6%) and CRIHA (71%). Only about 9% of stage 3a CKD patients 
from CRIHA were referred to a nephrologist. This proportion is slightly higher in ERIHA 
(12.2%) and Labrador-Grenfell (13.2%), whereas WRIHA showed the highest referral 
rates for CKD patients in that eGFR stage. 
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Table 7: Comparison of variables specific proportion of CKD population who were seen by a nephrologist:  
 Proportion of CKD population seen by a nephrologist 
by given characteristics 
 NL ERIHA CRIHA WRIHA G-Labrador 
Age, 18-39 32.3 28.5 35.1 59.6 50.0 
40-49 25.1 21.1 38.4 48.1 27.4 
50-59 19.9 16.3 23.7 37.3 24.6 
60-69 19.9 15.9 19.2 39.1 25.0 
70+ 21.5 16.2 16.8 46.4 19.6 
      
Sex, Male 24.0 19.0 22.5 46.9 30.3 
Female 19.3 15.1 16.5 40.8 17.9 
      
Diabetes status, Yes 26.4 21.5 22.4 48.0 28.1 
No 17.4 13.4 15.7 39.3 18.1 
      
eGFR <60 16.0 12.2 8.9 36.7 13.2 
<45 35.3 31.0 27.8 56.7 40.0 
<30 62.5 60.4 50.3 80.9 78.1 
<15 80.4 80.6 71.0 100.0 100.0 
      
Stable kidney 21.0 16.4 19.4 42.8 22.7 
Unstable kidney 25.0 22.2 15.5 60.3 20.9 
*all numbers are presented as %; eGFR=estimated glomerular filtration rate measured in ml/min/1.73m2; NL=Newfoundland and 
Labrador; RIHA=Regional Integrated Health Authority; ERIHA=Eastern RIHA; CRIHA=Central RIHA; WRIHA=Western RIHA;  
G-Labrador=Labrador-Grenfell RIHA
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3.7  Association between nephrologist visit and patients’ demographics and clinical 
characteristics 
The logistic regression analysis showed strong evidence of a difference between 
health regions and referral to nephrologist. (Table 8) Adjusted odds for nephrologist visit 
were 3.4 folds (95% CI, 2.9-3.9) for WRIHA, 0.5 (95% CI, 0.4-0.6) for CRIHA, and 0.8 (95% 
CI, 0.7-0.9) for ERIHA respectively compared to Labrador-Grenfell RIHA. Male CKD 
patients have a 1.4-fold (OR, 1.4; 95% CI, 1.3-1.5) (p < 0.001) higher chance of seeing a 
nephrologist than female individuals. The presence of diabetes demonstrated an 
association with a higher likelihood of a nephrologist visit (odds ratio: 1.4 CI, 1.3-1.5) (p 
< 0.001). CKD patients with unstable kidney function have a significantly higher chance 
of seeing a nephrologist than stable CKD patients (odds ratio: 2.2 CI, 1.9-2.4) (p < 0.001). 
The interaction term between Age and average eGFR is significant but does not 
show any higher or lower chance of seeing a nephrologist. The main effects of lower 
eGFR (OR, 0.8; 95% CI, 0.8-0.9) (p < 0.001) and younger age (OR, 0.9; 95% CI, 0.92-0.93) 
(p<0.001) may be associated with a greater likelihood of being seen by a nephrologist. 
Omnibus test of model coefficients based on the likelihood-ratio chi-square test 
showed that the overall model (with independent variables included) is predictive of 
nephrologist visit. Highly significant chi-square (6738.5, df=9, p< .001) suggests that the 
overall model of expecting a nephrologist visit is significantly better and more suitable 
compared to intercept-only base model. 
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Table 8: Multivariate logistic regression analysis for predictors of referral to nephrologists. 
 Variables in the Equation 
 
B SE Wald df 
Significance 
(p value) 
OR 
95% CI for OR 
Lower Upper 
Age (at baseline) -.074 .005 235.351 1 .000 .929 .920 .937 
Sex (Male) .352 .027 164.407 1 .000 1.422 1.347 1.500 
Diabetes status (Yes) .368 .027 178.934 1 .000 1.444 1.369 1.524 
ERIHA -.186 .075 6.125 1 .013 .830 .716 .962 
CRIHA -.581 .088 43.600 1 .000 .559 .471 .665 
WRIHA 1.224 .079 242.722 1 .000 3.402 2.916 3.968 
G-Labrador   2062.413 3 .000    
Kidney Function Stability (Unstable) .779 .067 135.329 1 .000 2.178 1.911 2.484 
Avg eGFR -.129 .007 365.836 1 .000 .879 .867 .890 
Age*Avg eGFR .001 .000 67.863 1 .000 1.001 1.001 1.001 
Constant 7.244 .364 395.068 1 .000 1399.17   
 
* The outcome in the regression was whether a person see a nephrologist or not?  
Variable(s) entered in the final model: Age (at baseline), Sex, Diabetes status, RIHA, Kidney Function Stability, Avg eGFR,  
Age*Avg eGFR; eGFR=estimated glomerular filtration rate measured in ml/min/1.73m2; B=Beta coefficient; SE=standard error; 
df=Degree of freedom; OR=odd ratio; CI=Confidence interval; Avg eGFR= Average eGFR; RIHA=Regional Integrated Health Authority; 
ERIHA=Eastern RIHA; CRIHA=Central RIHA; WRIHA=Western RIHA; G-Labrador=Labrador-Grenfell RIHA
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3.8  Kidney care delivery 
Overall, 7.36% of CKD patients were in contact with nephrologists, irrespective of 
age, sex and level of kidney dysfunction within one year of CKD recognized. The rate was 
10.81% within two years after recognition. The proportion of nephrologist visits were 
16.03% and 24.27% in the first and second year, respectively, for CKD patients in the 
Western Health Region. The Eastern, Central and Labrador-Grenfell Health Regions were 
5.76% and 8.17%, 5.40% and 8.88%, 7.02% and 10.82%, respectively. Among CKD 
patients within the Western Health authority, Corner Brook had the highest rate of 
nephrologist visits within one and two years after CKD recognition (21.07% and 30.53%, 
respectively). If a CKD patient is living in St. John’s, he or she is about 6.6% and 9.5% 
likely to see a nephrologist within the first and second year, respectively, after CKD 
recognition. If a patient is living in Corner Brook, he or she is much more likely to see a 
nephrologist (Table 9). 
As expected, the age-specific rates of young CKD patients, aged 18-39, had the 
highest nephrologist visits among all age groups within both one and two years after 
recognition. Rates also increased in patients with diabetes compared to patients 
without diabetes. Female individuals were less likely to have nephrologist visits than 
male individuals (6.7% vs 8.4% in the first year and 9.9 vs. 12.2% in the 2nd year, after 
CKD recognition) (Table 10). 
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Table 9: Distribution of CKD by nephrologist visit within one and two years following 
recognition by RIHAs and communities 
 
 
Nephrologist visit 
within 1yr after 
recognition 
Nephrologist visit 
within 2yrs after 
recognition 
Overall, NL (N=40465) 7.36 10.81 
ERIHA (N=29457) 5.76 8.17 
CRIHA (N=3354) 5.40 8.88 
WRIHA (N=6237) 16.03 24.27 
G-Labrador (N=1239) 7.02 10.82 
   
Communities   
ERIHA (N=29457):   
St. John's (N=9457) 6.59 9.49 
Carbonear (N=657) 3.35 4.87 
Burin (N=198) 5.56 6.57 
Clarenville (N=1070) 2.90 4.02 
Bonavista (N=670) 4.03 6.12 
   
CRIHA (N=3354):   
Gander (N=355) 3.38 7.32 
Grand Falls Windsor (N=483) 4.55 8.49 
   
WRIHA (N=6237):   
Corner Brook (N=2126) 21.07 30.53 
Stephenville (N=500) 9.40 15.00 
Channel Port Aux Basques (N=509) 11.79 19.25 
   
G-Labrador (N=1239):   
St. Anthony (N=181) 6.63 10.50 
Happy Valley-Goose Bay (N=140) 8.57 10.13 
Labrador City (N=79) 6.33 10.13 
*N=number of CKD (as denominator); numbers are presented as %;  
NL=Newfoundland and Labrador; RIHA=Regional Integrated Health Authority;  
ERIHA=Eastern RIHA; CRIHA=Central RIHA; WRIHA=Western RIHA;  
G-Labrador=Labrador-Grenfell RIHA  
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Table 10: Distribution of CKD in NL by nephrologist visit within one and two years 
following recognition by age, sex and diabetes status 
 
 
Nephrologist visit 
within 1yr after 
recognition 
Nephrologist visit 
within 2yrs after 
recognition 
Age groups, 18-39 (N=561) 11.9 18.2 
40-49 (N=1,970) 8.3 12.1 
50-59 (N=5,918) 6.9 10.2 
60-69 (N=12,048) 6.7 10.0 
70+ (N=19,865) 7.7 11.2 
   
Gender, Male (N=15,948) 8.4 12.2 
Female (N=24,516) 6.7 9.9 
   
Diabetes status, Yes (N=16,663) 9.0 13.3 
No (N=23,802) 6.2 9.0 
*N=number of CKD (as denominator); all numbers are presented as %;  
RIHA=Regional Integrated Health Authority; NL=Newfoundland and Labrador  
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3.9 Direct age-standardized rate for nephrologist visits 
CKD patients seeing nephrologists from the Eastern Health region experienced 
rates similar to the provincial rates (7-9 per 1,000). The communities with the highest 
number of male and female CKD patients seeing nephrologists were found in the 
Western Health Region (around 17 per 1000) throughout the study period. As expected, 
the rates in Central and Labrador-Grenfell were much lower (2-5 per 1000), compared 
to the NL average (Figure 5). 
Also, when compared to the age-standardized number of visits to a nephrologist 
by CKD patients per 1,000, the Western Health Region population (both male and 
female) showed higher rates than the other three health regions (for example, in 2013, 
visit rates to a nephrologists were 30.80 per 1,000 in the Western Health Region 
compared to 16.97, 8.24, and 6.53 in the Eastern, Central and Labrador-Grenfell Health 
Regions, respectively) (Figure 6). 
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(A) Male          (B) Female 
Figure 5: Age-adjusted nephrologist visit by sex across health regions. 
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(A) Male          (B) Female 
Figure 6: Frequency of age-adjusted nephrologist visit by sex across health regions. 
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3.10  Factors influencing the frequency of nephrologist follow-ups 
The odds ratios of nephrologist visits were 1.5 (CI: 1.4-1.6, p<.0001), 1.4 (CI: 1.3-
1.4, p<.0001), 1.4 (CI: 1.3-1.44, p<.0001), and 1.2 (CI: 1.1-1.2, p<.0001) times higher 
for the young adult (18-39 years), 40-49, 50-59, and 60-69 age groups, respectively, 
compared to the age group of 70 years and over. Nephrologist visit frequency 
decreased as average age increased. (Table 11) 
Female CKD patients had a lower likelihood of seeing a nephrologist in 
comparison to their male counterparts (OR=1.2, 95% CI: 1.2-1.3, p<.0001), as 
determined after adjusting all independent variables in the Poisson regression 
model. Follow up frequency was slightly higher for diabetic CKD patients than for 
those who had CKD with no diabetes mellitus (OR=1.1, 95% CI: 1.0-1.1, p<.0001). 
The frequency of nephrologist visits varied by the level of kidney dysfunction. 
Using the average eGFR values over the study period from 2011-2015, low eGFR 
patients (stage 5 CKD, <15ml/min/1.73m2) showed higher odds (OR=4.0, 95% CI: 3.8-
4.3, p<.0001) than people with an eGFR over 60 ml/min/1.73m2 after adjusting all 
other variables in the model. The next most frequent nephrologist visits were 
observed among patients with stage 4 CKD (OR=2.3, 95% CI: 2.2-2.4, p<.0001) 
followed by stage 3b CKD (OR=1.3, 95% CI: 1.3-1.4, p<.0001).  
Regional differences were also observed. The Eastern, Western and Central 
integrated health regions were associated with the likelihood of higher frequency of 
nephrologist visits compared to Labrador-Grenfell (OR=1.8, 95% CI: 1.7-2.0, p<.0001; 
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OR=1.7, 95% CI: 1.6-1.8, p<.0001; and OR=1.3, 95% CI: 1.2-1.4, p<.0001, 
respectively).  
Chronic kidney disease patients with unstable kidney dysfunction (patients with 
a rate of kidney function decline of more than 10ml/min/1.73m2 eGFRMDRD per year 
on average) were found to have an odd pattern of care. There was 10% lower 
chance of having frequent nephrologist-visits (OR=0.9, CI: 0.8-0.9, p<.0001) for 
unstable kidney function patients than those with stable kidney dysfunction. It is 
possible that nephrologists may ignore previous follow ups and overlook the change 
of kidney function; rather they look at the current or most recent kidney function 
test reports.  
Omnibus test showed statistically significant fitted model (LR chi-square 5576.3, 
df=14, p<.001) against the intercept-only model. A diabetic younger male with low-
average eGFR per year and unstable kidney function were seen more frequently by a 
nephrologist. CKD patients living in Labrador-Grenfell were related to the likelihood 
of being seen by a nephrologist less frequently than those living in other health 
regions.  
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Table 11: Poisson loglinear regression analysis of factors associated with number of nephrologist visits following referral; 
parameter estimates from SPSS output 
Parameter B SE 
95% Wald CI Hypothesis Test 
OR 
95% Wald CI for OR 
Lower Upper 
Wald Chi-
Square 
df P value Lower Upper 
(Intercept) .348 .0414 .267 .429 70.869 1 .000 1.417 1.306 1.536 
Age=18-39yrs .384 .0354 .314 .453 117.251 1 .000 1.468 1.369 1.573 
Age=40-49yrs .323 .0233 .278 .369 192.787 1 .000 1.382 1.320 1.446 
Age=50-59yrs .337 .0160 .305 .368 440.783 1 .000 1.400 1.357 1.445 
Age=60-69yrs .174 .0131 .149 .200 177.073 1 .000 1.190 1.160 1.221 
Age=70+yrs 0a       1   
Sex=Male .210 .0108 .189 .231 376.826 1 .000 1.233 1.208 1.260 
Sex=Female 0a       1   
Diabetes status=Yes .081 .0110 .059 .102 54.014 1 .000 1.084 1.061 1.108 
Diabetes status=No 0a       1   
ERIHA .597 .0374 .524 .670 255.355 1 .000 1.817 1.688 1.955 
CRIHA .230 .0421 .147 .312 29.824 1 .000 1.258 1.159 1.367 
WRIHA .527 .0382 .452 .602 190.282 1 .000 1.694 1.572 1.826 
G-Labrador 0a       1   
Avg_eGFR<15 1.396 .0345 1.328 1.464 1634.290 1 .000 4.039 3.775 4.322 
Avg_eGFR<30 .835 .0187 .798 .871 1989.222 1 .000 2.304 2.221 2.390 
Avg_eGFR<45 .294 .0178 .259 .329 274.352 1 .000 1.342 1.296 1.390 
Avg_eGFR<60 -.074 .0178 -.109 -.039 17.374 1 .000 .929 .897 .961 
Avg_eGFR>=60 0a       1   
Kidney function=Unstable -.115 .0293 -.172 -.057 15.334 1 .000 .892 .842 .944 
Kidney function=Stable 0a       1   
(Scale) 1b          
*Dependent Variable: Frequency of nephrologist Visits; Model: (Intercept), Age, Sex, Diabetes status, RIHA, Avg_eGFR, Kidney function stability;  
a. Set to zero because this parameter is redundant. b. Fixed at the displayed value; B=Beta coefficient; SE=standard error; df=Degree of freedom; 
OR=odd ratio; CI=Confidence interval; Avg eGFR= Average eGFR; RIHA=Regional Integrated Health Authority; ERIHA=Eastern RIHA;  
CRIHA=Central RIHA; WRIHA=Western RIHA; G-Labrador=Labrador-Grenfell RIHA 
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3.11 Status of referral to a nephrologist for CKD patients 
Eight thousand eight hundred and fifty CKD patients were referred to 
nephrologists by family physicians over the study period from 2011 to 2015. Patient 
referral was determined when a patient with CKD appeared to have been seen by a 
nephrologist.  
Among those with CKD stage 3a, younger CKD patients composed the largest 
age-group (35.4%), while those aged 40-49 constituted 27.2% of the CKD stage 3a group 
(Table 12). Those aged 70+ constituted the smallest age group at 14.3% of the CKD stage 
3a group. It is noticed that the lower the eGFR the greater the proportion seen by a 
nephrologist across all age groups and irrespective of gender and diabetes. 
More male CKD patients were referred to nephrologists than were female CKD 
patients in all stages [Stage 3a, (18.9% vs 14.2%), Stage 3b (41.4% vs 31.7%), Stage 4 
(71.1% vs 57.5%), and Stage 5 (84.2% vs 78.4%)].  
Diabetic patients at CKD stage 3a or above tended to be referred more 
compared to CKD patients without diabetes (19.3% vs 14.0 at stage 3a, 38.9% vs 31.6% 
at stage 3b, 65.0% vs 59.1% at stage 4, and 81.3% vs 79.2% at stage 5). 
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Table 12: Proportion of NL CKD patients (at given characteristics) referred to a 
nephrologist by stage. 
 
 eGFRMDRD  (ml/min/1.73m2) 
 <15 <30 <45 <60 
Age groups, 18-39 100.0 100.0 72.7 35.4 
40-49 100.0 87.8 68.1 27.2 
50-59 100.0 84.6 59.4 17.5 
60-69 88.9 82.6 46.6 15.9 
70+ 74.4 56.0 28.6 14.3 
     
Sex, Male 84.2 71.1 41.4 18.9 
Female 78.4 57.5 31.7 14.2 
     
Diabetes status, Yes 81.3 65.0 38.9 19.3 
No 79.2 59.1 31.6 14.0 
*all numbers are presented as %; eGFR=estimated glomerular filtration rate measured in 
ml/min/1.73m2 
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3.12 Proportion of CKD patients receiving nephrology service within their own 
region 
Considering nephrology service delivery by health region, 90% of CKD patients 
from ERIHA are seen by a nephrologist within their region of residence. By contrast, 
many CKD patients living in other heath regions have been seen by a nephrologist in a 
hospital located in another health region. 74.3%, 68.6%, and 64.1% of CKD patients from 
CRIHA, WRIHA and Labrador-Grenfell RIHA, respectively, were only seen by a 
nephrologist in their respective regions. This means the rest, 10%, 25.7%, 31.4%, and 
35.9% of CKD patients from ERIHA, CRIHA, WRIHA and LG RIHA, respectively, were seen 
elsewhere to have a nephrologist visit or have seen other specialists like general internal 
medicine specialist. 
 
3.13 As requested by the patients’ partners, we looked at the following  
3.13.1 Distribution of CKD in Indigenous community 
In the Labrador-Grenfell health region, 1,239 patients were recorded as 
identifiable CKD patients from a total population of 37,229. In this database, forty-six 
communities from Labrador-Grenfell health region were recorded based on the 
patients’ postal code information. As the data do not specifically identify people as 
being of Indigenous origin or not, the community of residence was used as a proxy for 
Indigenous status.  Three large communities (Labrador city with a population of 9,228, 
HVGB with 8,109, and St. Anthony with 2,418) were analyzed separately, representing a 
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majority (over 78% on average) Caucasian population. The coastal communities, with a 
combined population of 9,282, were analyzed together, where over 85% of the 
population was Indigenous on average. Of this latter group, only 133 (1.4%) were 
documented as identifiable CKD patients. Whereas 7.5% (181), 1.7% (140), and 0.9% 
(79) of the population were identifiable CKD patients in Caucasian majority St. Anthony, 
Happy Valley-Goose Bay and Labrador city, respectively. 
Age was a significant factor in CKD prevalence for the Indigenous population: the 
rate of CKD increased with age. Among the Indigenous CKD patients, half of them 
(50.3%) were in the 70+ group and 31.6% and 13.3% were in the 60-69 and 50-59 age 
groups, respectively. In comparison, in Labrador city, only 24% of CKD patients were 
aged 70+. In the other two large cities, St. Anthony and Happy Valley-Goose Bay, the 
proportion of CKD patients aged 70+ was similar to the proportion of those aged 70+ in 
the Indigenous communities at large (49.7% and 43.6%, respectively).  
Females comprised 59.7% of Indigenous CKD patients and males comprised 
40.3%. Among the non-Indigenous CKD patient population from St. Anthony, Labrador 
City and HVGB, 69.6%, 57%, and 63.6% were female, while 30.4%, 43%, and 36.4% were 
male, respectively.  
47% of the Indigenous CKD population were suffering from diabetes mellitus, 
while 43.1%, 39.2%, and 46.4% of the non-Indigenous CKD patient population from St. 
Anthony, Labrador city and HVGB, respectively, were diabetic. 
77 
 
When considering the 5-year average eGFR, half of the Indigenous CKD patients 
fell into CKD stage 3a, 22.8% into CKD stage 3b, and 6.2% into CKD stage 4. 
 
3.13.2 Proportion of people with diabetes tested for CKD 
From 2011 to 2015, in Newfoundland and Labrador, 76,692 diabetic patients 
were recorded. 40,465 individuals were identifiable as CKD patients by CKD operational 
definition. Among them, 16,663 individuals had both diabetes and CKD. The first line 
screen for diabetes is a urine protein test. Among diabetic patients, only 12.8% (9,790 
individuals) patients were tested for urine albumin creatinine ratio which demonstrated 
a huge gap in CKD screening services in diabetic patients. On the other hand, only 4.5% 
of CKD patients had urine analysis done which is an underutilization of urine testing, a 
key investigation that the care providers are not doing.  
 
3.14 Outcomes of patient engagement 
 Patients’ partners were not actively involved in accessing the CKD data. We sent 
out the thesis to all of them and asked if they had any comments or questions or if they 
think that we should meet and discuss their concerns. To this point, none have provided 
any feedback about what they believe the data have shown. This could mean any 
number of things; e.g. they did not read the thesis, they read the thesis but did not 
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understand it, or, they did not have any comments or questions. We will contact the 
patient partners and try to engage again to discuss their impressions. 
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Chapter 4: Discussion 
 
4.1 Introduction 
This study estimates the prevalence of chronic kidney disease in the province of 
Newfoundland and Labrador, Canada. To the best of our knowledge, this is the first 
study to describe CKD prevalence over a 5-year (2011-15) period in the province. Our 
analysis showed a relative agreement with Statistics Canada. Also, results are consistent with 
other reported population-based studies23,125 although the assessments among other 
studies have variations due to their different settings and varying CKD definitions and 
identification methods.  
In our study, we identified CKD cases based on eGFR values only. An eGFR below 
60 ml/min/1.73m2 at two points, at least 3 months apart, was considered indicative of 
CKD. Urine analysis, another valuable marker for CKD identification, was not taken into 
consideration because the relevant digital data was difficult to analyze due to the 
variable methods of urinalysis and the relative infrequency of urine studies. 
 
4.2 Summary  
Chronic kidney disease is an ongoing health concern in NL. This study describes 
recent CKD prevalence, as well as the gaps in kidney care (i.e. lack of nephrologist visits 
and risk identification testing). Understanding what demographics were best able to 
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access proper nephrology services will help with future planning to provide kidney care 
access in high-risk health regions. The study observed the regional differences in 
accessing kidney care. The CKD patients from Labrador-Grenfell health regions 
experience from the least likelihood of nephrologist visits compared to the other health 
regions. For those with unstable kidney function, it was found that there was a 10% 
lower chance of having frequent nephrologist-visits (OR=0.9, CI: 0.8-0.9, p<.0001), 
compared to those with stable kidney dysfunction. An Underutilization of combined 
eGFR and urine tests was found for targeted CKD cases among diabetic patients. Only 
12.8% of diabetic patients have been tested for their urine albumin-creatinine ratio, 
which demonstrates a huge gap in CKD screening services for diabetic patients. On the 
other hand, only 4.5% of CKD patients had a urine analysis done. We found the CKD 
prevalence among the Indigenous community troubling. We may have only seen the tip 
of a bigger CKD population as a much smaller number of people with CKD were 
identified in the Indigenous community compared to Caucasians. This finding 
demonstrates that we may need to focus on CKD screening first and identify people with 
CKD among the Indigenous population. 
 
4.3 Management of CKD 
It is important for healthcare providers to identify patients with unstable CKD 
and provide an early referral to a nephrologist for a better outcome. Considering kidney 
function stability, the ERIHA, CRIHA, and Labrador-Grenfell health region each showed 
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huge potential gaps in care where only 22.2%, 15.5%, and 20.9% of unstable CKD 
patients were seen by a nephrologist, respectively. By contrast, in WRIHA, 60.3% of 
unstable CKD patients were seen by a nephrologist; this reflects the most efficient 
referral by family physicians among the four health regions (Table 7).  
Results showed that diabetic individuals, who had significantly unstable kidney 
function, had a significantly higher chance of seeing a nephrologist (Table 8). When we 
considered the frequency of nephrologist visit, Statistical analysis (Poisson analysis) 
showed that unstable CKD patients were not visiting nephrologists more often than 
stable CKD patients (Table 11). Progressive CKD patients had 10% lower chance to have 
frequent nephrologist-visits (OR=0.9, CI: 0.8-0.9, p<.0001) as opposed to those with 
stable kidney dysfunction. This appears to be an inefficient pattern of care. 
Nephrologists, on the other hand, should be able to identify whether a patient has 
stable or unstable kidney function and consider this in choosing to follow up the patients 
frequently.126 But in reality, they may not bring the progressive patients back for frequent 
visits. This odd pattern of kidney care from practitioners needs attention.  
 
4.4 Factors influencing referral to nephrologists 
Consistent with previous studies127, we found that family physicians 
preferentially refer younger people with CKD to nephrologists. Analysis showed that, 
compared to older CKD patients, a higher proportion of young people with a low eGFR 
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has been seen by a nephrologist within the first and second year after CKD 
identification. This might be clinically appropriate if younger people are given more 
priority because they have a greater risk of longer-term consequences than an older 
person. The same is true for diabetic patients.128 More diabetic patients with CKD have 
been seen by a nephrologist within the first two years than those without diabetes. It 
should be equally likely for both men and women with CKD to be referred to and seen 
by a nephrologist. In our findings, male individuals were more likely to have 
nephrologist visits than female individuals (8.4% vs. 6.7% in the first year and 12.2% vs 
9.9% in the 2nd year, after CKD recognition).     
 
4.5 Kidney care services and CKD 
The study revealed regional variations in the average frequency of nephrologist 
visits within the province. Patients living in St. John’s in ERIHA are far less likely to be 
seen by a nephrologist within 1 and 2 years after CKD recognition (7% and 10%, 
respectively), compared to patients living in Corner Brook in WRIHA (21% and 31%, 
respectively).  
This study is intended to identify gaps in kidney care service. One potential gap 
in service is that the CKD patients are not seeing a nephrologist, while referral at early 
CKD stage plays an important role129 in CKD management. We found that only 35.4% of 
CKD patients aged 18-39 were referred to a nephrologist at CKD stage 3a (Table 12). 
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Only 19.3% of diabetic patients were referred to a nephrologist at CKD stage 3a. 
Another gap might be in the management of unstable kidney function decline. The study 
found that patients with unstable CKD living in the Central health region have a much 
lower chance of seeing a nephrologist than unstable CKD patients living in the Western 
health region. Only 21.8% of CKD patients see a nephrologist in NL (compared to 21.7% 
for non-Hispanic white individuals in USA in 2012130). It is possible that the actual 
number of individuals with CKD in the general population is much greater than the 
number of individuals with CKD who have been referred to a nephrologist. 
The higher rate of nephrologist visit frequency in the Western Health Region may 
be due to the fact that the nephrologists practicing in this region also practice internal 
medicine and thus may see their patients more often to deal with other health 
conditions. Given that there are two nephrologists in the western RIHA, and that they 
make up about 20% of the Internal Medicine specialists there, GPs in the region will 
choose to refer to them more often. By contrast, in St. John’s, for example, GPs choose 
to refer to a cardiologist, internal medicine specialist etc. instead if they wish. 
Some people who are unstable may not see a nephrologist frequently. Among 
different health regions, there are differences in number of CKD patients referred and 
frequency of nephrologist visits. We do not know the optimum proportion of CKD 
patient to be seen by a nephrologist. So it is possible that in WRIHA, nephrologists may 
be over practicing compared to other health regions or vice versa.  
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Many CKD patients were not seen within their respective health region according 
to their residence. 25.7% of CKD patients from CRIHA, 31.4% from WRIHA and 35.9% 
from Labrador-Grenfell health regions were receiving the nephrology services from 
other health regions compared to 10% of CKD patients from ERIHA. Clearly, this lack of 
nephrology services does not meet the required kidney care need in place, except ERIHA 
(10%) or they could had seen by other specialist like general internal medicine specialist. 
There is no nephrologist practicing in CRIHA and Labrador-Grenfell RIHA. One 
nephrologist from St. John’s periodically travels to clinics in CRIHA and LG-RIHA. Another 
nephrologist travels to clinics in only Labrador City once a year. This makes it arguable 
that there are enough CKD patients there to justify at least one nephrologist in each 
health region. 
Healthcare providers are not using the best information they have to risk stratify 
patients. Only 4.5% of CKD patients and 12.8% of diabetic patients had urine albumin 
creatinine ratio test done. This is very low and inhibits using a predictive score to 
identify kidney disease. This may also mean that GPs are not picking the highest-risk 
patients either to refer or follow more closely. We recommend more urine analysis both 
for diabetics and CKD screening procedures. We may also need to do albumin creatinine 
ratio test to fully understand the patients’ kidney condition by using a risk stratification 
matrix. 
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4.6 Age distribution among patients identified with CKD 
We found that, depending on the age group, older people in Labrador city are at 
a lower risk of having CKD than older people elsewhere. However, this finding may not 
be viable. This statistic may not indicate the nature of disease, but rather, the nature of 
the population structure of this particular city131. In Labrador city, of those with CKD, 
most are middle aged. Older people after retirement tend to leave the city, meaning 
that there are fewer older CKD patients there. If we looked at all the sick people in 
Labrador City, they largely will be middle aged individuals because they have not yet left 
the city. While, generally, all older people, including those who become sick and/or 
retire, tend to leave the city.  
 
4.7 Gender and sex-based analysis and identified bias 
We acknowledged the differences of prevalence of CKD between men and 
women. The same pattern can be observed in an end stage kidney disease treatment 
across the country as evidenced by CORR data. The CORR data [Appendix E] on dialysis 
mirrors our finding that men tend to have more progressive CKD than women.132 CORR 
shows only end stage kidney disease, but this is only the tip of the iceberg of CKD. 
Dialysis patients across the country all show the same pattern whereby more men are 
recognized with kidney disease than women. This may not be a distinctly socio-cultural 
phenomenon but simply be that a higher proportion of people reaching end stage 
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kidney treatment are men. It is not that women are under-diagnosed or under-treated. 
There is no reason to believe that there is a bias that leads family physicians to select 
men over women for treatment. If there are more men than women with CKD anyway, 
then we can simply assume that men are at risk. This is different to experience of 
women versus men receiving health care in general.133 
 
4.8 Prevalence of CKD among the Indigenous population 
The populations of St. Anthony, Labrador City and Happy Valley-Goose Bay are 
mixed (mostly Caucasian); but, along the coastline of Labrador, cities/towns (e.g. 
Natuashish and Sheshatshiu) the population is predominantly Indigenous. Thus, if we 
discuss the prevalence of CKD there, we discuss the prevalence of CKD among people of 
Indigenous origin. Any communities other than St. Anthony, Labrador city and HVGB 
were considered a potentially Indigenous population. To draw conclusions about 
Indigenous populations, we simply left out the towns with mixed populations and higher 
proportions of Caucasian individuals. 
We grouped all largely Indigenous communities in Labrador and identified the 
proportion of this group with chronic kidney disease. This is not a prospective survey; 
when discussing prevalence, we are dealing with what we already know. We are not 
sure how many people actually have kidney disease in real time; we only know how 
many of them we have identified based on the existing test results. There can be 
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differences between the actual number of patients with CKD and the number of those 
identified as CKD patients. Thus, we must be careful not to say that there are fewer 
people with CKD from the Indigenous community; that is, we only know that fewer 
people with CKD were identified. Lower CKD prevalence in Indigenous communities may 
indicate that problems are not accurately being recorded in the EMR. It may be due to 
the way where the information is captured, or there are not enough blood tests done by 
primary care providers to diagnose CKD. For that, we may need to do more blood work 
to understand the bigger problem. For example, Sheshatshiu, an Innu community close 
to Happy Valley-Goose Bay, has a very large number of people on dialysis and thus, it is 
probable that it also has a large number of people with CKD. Within the Indigenous 
population, and especially those living in remote locations, the real issues are access to 
care, early diagnosis, and the possibility that individuals diagnosed with kidney disease 
will have to leave their community for care. 
 
4.9 Study limitations  
People with two consecutive eGFRs below 60 ml/min/1.73m2 at least 3 months 
apart were identified as CKD patients. This operational definition is a bit arbitrary as we 
ignored urinary protein and the eGFRs itself can be inconsistent. Because of the way 
that this analysis has been conducted, errors are possible since we may misclassify 
people at different points of time. While all people in the dataset met the definition at 
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some point during the period, they may not have met the definition at all time points. 
For this reason, we used patients’ average eGFRs over the whole study period and 
grouped people by CKD Stage by their average eGFRs per year. For example, if we say 
that someone is in CKD stage 4, we mean that their average eGFR was within the range 
of 15-29 ml/min/1.73m2 for that particular year, or for the whole period of time. 
 Moreover, Urine analysis (proteinuria/albuminuria) was not taken into account 
to define CKD in this study because of the limited availability of the relevant electronic 
medical data due to the variable methods of urinalysis. This relates to the ascertainment 
bias in which many CKD patients were not included, or less likely to be included in the 
study database. This unavoidable systematic distortion of the data restricted the exact 
representation of CKD prevalence in the province. 
There is a possibility of under- or over-testing certain age groups, relative to one 
another. This could affect our understanding of the proportions of the CKD patient 
population composed by different age groups. The study may not really document the 
prevalence of CKD as much as it documents the prevalence of potentially recognizable 
CKD. This is important because changes in patterns of ordering blood tests, in 
accordance with developments in policy and associated guidelines, will also change the 
apparent frequency of CKD.  
The limitations associated with the retrospective study design limit the reliability 
of the study results. The retrospective aspects of this kind of administrative data may 
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introduce misclassification or information bias, for which the temporal relationship is 
often difficult to assess. However, such a large population dataset like that included in 
this study indicates that there will be some definitive evidence concerning CKD 
prevalence. 
The data entirely depends on lab reports. Errors could have occurred (eg. male, 
female coding error) and there is no way of knowing if or how often such errors 
occurred. Thus, any of the data fields could contain errors, and we do not really know 
the likelihood of this. With regards to the laboratory values of eGFR and claim 
ascertainment, we acknowledge that there were up and down swings in the eGFR 
values. We acknowledge that there are some rather extreme values that seemed 
improbable from the clinical point of view that we chose to leave out of analyses as 
these are a very small proportion of the whole data set. 
Any conclusion we have reached is based on the analysis of the vast majority of 
cases; this minimizes the limitation of missing information.  
In the analyses, the smaller communities were ignored as there were insufficient 
cases to draw conclusions about them. One of many analytic challenges regarding small 
data from the remote communities was that the low accessibility of the population 
made it problematic to see the actual picture of CKD prevalence. The issue with the 
small data from remote communities is a barrier to addressing persistent unsolved 
research in many of the public health challenges including CKD. 
90 
 
Using secondary data causes limitations as there may have been errors with the 
initial recording or in the transfer to the study database. There are two common errors 
found in retrospective laboratory test data reviews: measurement errors, which are 
made in the recording of continuous variables, and misclassification errors, which are 
made in the recording of categorical variables. Measurement errors may be widespread 
when serum creatinine as a measurement of kidney function is not measured with the 
same calibrated scale for each individual in different communities. Indeed, different 
health regions were reporting kidney function in different mnemonics, such as 
Creatinine, GFRMDRD, EGFRC, EGFRCALC, etc.  
Prevalence of CKD in the first year (year of 2011) was not complete, as eGFR 
laboratory test results were recorded starting from April of that year instead of from 
January, 2011. Individuals were grouped into five age categories (18-39, 40-49, 50-59, 
60-69, and 70+ years) based on their age at the baseline year 2011 and this was not 
changed year by year. This means that as people aged >70 years passed away, they 
were not replaced by people who were 69 years old in 2011.  
Some people who truly have CKD would have a single final creatinine in 2011 while 
others would have a single first creatinine in 2015. Both were excluded from the original 
data due to not meeting the case definition and may cause an artefact. 
One of the issues of ‘Ecological Fallacy’ is the confusion between individual 
correlations and ecological correlations. In this study, we used Labrador coastal 
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communities as a proxy of being Indigenous and interpret group level data on the 
individual level. If, as part of the CAN-SOLVE-CKD initiative, the results of this study are 
utilized to contribute to a larger prospective study of greater duration and geographical 
distribution covering the whole of Canada, this limitation will be avoided. 
Other markers of care such as blood pressure, use of appropriate medications to 
reduce CKD progression and cardiovascular benefit (ACEi/ARBs, statin) are not included 
in the analysis as these data were not available. NLCHI does not capture the blood 
pressure data as it is an in-office reading. When EMR becomes the norm, we may have 
blood pressure records in the database in the future. There was no active pharmacy 
network data (record of medication data) at the time of the study period, i.e., between 
2011 and 2015, which would have allowed us to include use of appropriate medication 
in the analysis.  
 
4.10 Significance of findings 
The results of this study may be utilized to contribute to a larger prospective 
study of large duration and geographical distribution that will cover the whole of 
Canada as part of the CAN-SOLVE-CKD initiative. Ultimately, the hope is to utilize the 
results in pre-emptive evidence-based planning and development for healthcare 
services and research studies that will enhance resource utilization and cost 
effectiveness in the provision of kidney care services in NL.  
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The goal of this project is to improve kidney care delivery for individual and 
population level CKD management with the aim of improving outcomes and quality of 
life for CKD patients and reducing overall healthcare costs for populations with CKD by 
reducing hospital admissions and procedures (e.g. dialysis). These improvements will be 
based upon the establishment of spatially enabled kidney care data structures that 
facilitate the performance of province-wide area analyses. Such applications are as 
follows: CKD surveillance; kidney care access using network analysis; community health 
profiling to address nephrology service delivery and healthcare disparities for CKD patients living 
in the underserved communities within the province. This provides both patients and 
providers with a greater understanding of the factors that affect the kidney health 
status of targeted populations. Keeping this in mind, this patient-oriented study would 
allow both patients and healthcare providers to be more aware of CKD than at any time 
in the past.  
Distributing this information may facilitate early diagnosis and intervention, and 
increase the awareness of kidney disease and its prevention. Finally, a decrease in CKD 
incidence and a reduction in exposure to various risk factors may improve patients’ 
quality of life and decrease societal burden and health-care costs. 
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4.11  Conclusions and recommendations 
We have reached a number of conclusions based on what we have observed in 
the data. We concluded that there are differences between regions in CKD prevalence. 
There is limited access to specialist kidney care in NL. People who have more 
progressive disease were not seeing a nephrologist more often compared to the people 
with non-progressive CKD. Our recommendation is that the nephrologists should review 
their re-booking decision making. Further, we also found that kidney specialty services 
in NL are poorly distributed geographically. Some people with CKD need to see a 
nephrologist from other health regions to receive kidney services. One strategy to 
minimize this gap in care is to employ a nephrologist in the Central regions. The 
population size in CRIHA justifies having a nephrologist on the ground, rather than their 
being dependent on the outreach clinic. In other regions (WRIHA and Grenfell-Labrador 
health region), the density of CKD patients is not sufficient to justify having more 
nephrologists. However, to serve their needs, distance methods such as e-consults, 
telehealth, etc., could be enhanced. 
There is an under-utilization of urine testing. This indicates a need to adopt the 
risk stratification method to observe patients’ CKD status. We need to determine 
whether this is a result of a knowledge gap amongst primary care practitioners or 
resistance from the patient; this could be a question to address in a future research 
context. The answer to this question will probably drive the intervention. For example: if 
the low testing rate is a result of a knowledge gap, continue medical education might 
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work to increase uptake of proteinuria/albuminuria testing in primary care in NL. These 
are all actionable, relevant, and impactful findings that could lead to improvements of 
care. Their most important potential impact is to incite future changes in kidney care. 
Kidney care in Newfoundland and Labrador refers to the planned use of 
nephrology service resources that respond in real time to kidney problems.134 We 
recommend further work in this regard on spatial GIS analysis that includes ‘spatial 
auto-correlation’, ‘hotspot analyses’ and ‘network analyses’. 
Practices adopted in the province at the moment are focused mostly on a 
passive approach that waits for patients to visit a kidney care center. Robert et al.135 
concluded that referral of all CKD patients to nephrologists is impractical. There are only 
11 nephrologists in NL according to a 2015 report by the Canadian Medical Association 
(CMA).136 CKD is being managed mostly by primary care providers following available 
guidelines. We need a system for early detection in high risk groups that screens CKD 
patients at the primary care level by integrating interdisciplinary services and employs 
appropriate management strategies (e.g. greater use of urine protein measurements to 
risk stratify, visualization tools to see change in kidney function over time, prompts to 
refer to a nephrologist in a timely manner etc.). Another option includes increasing the 
number of nephrology outreach teams. These teams seek CKD patients around the 
province and provide evidence-based kidney care delivery at a reasonable cost. 
Outreach programs are important especially for underserved communities in remote 
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locations and communities in which individuals have difficulties accessing proper 
care.137 With telehealth, patients in remote communities may benefit from nephrologist 
access, regardless of location.138 Telehealth allows remote communities to receive the 
care required, first to identify and then to manage CKD. Also, electronic consultation 
(eConsult) may allow primary care providers direct access to a nephrology consultant to 
assess the right course of action for CKD patients, avoiding unnecessary referrals.139 It 
also increases access to kidney care services at the point of care.  
More research is needed to understand the interaction between kidney care and 
geography such as regional influences, care disparities within remote communities etc.         
To improve health outcome in remote communities, we need to make sure that we take 
into account the specific challenges that these population face, considering the impact 
of social determinant on health among and within each of these groups; while we 
advance our understanding of the unique needs of each health region. From an 
awareness perspective, the public recognition140 of the seriousness of CKD and how it 
leads to ESKD is important.  
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Appendices 
Appendix A: Invitation to all practicing nephrologists in NL asking permission for data 
use 
 
Dr. Brendan Barrett MB, MSc, FRCPC  
Professor of Medicine (Nephrology) 
 
(On behalf of Dr. Mohammad A. Hossain, MBBS 
Masters student, Dept. of Clinical Epidemiology 
Memorial University of Newfoundland) 
 
 
Dear colleagues, 
 
I am in the process of putting together a project that would look to map the density and 
location of CKD cases in the province as a whole. This can be done using existing lab 
datasets available at the Centre for Health Information. They have lab data from 2011 to 
2015.  In addition to mapping where those with the problem live I would also like to 
map where and when they are seen by a nephrologist. That could be done by linking to 
fee for service claims.  We would not be using any identifiers for any of this, however 
given there are only 10 or so nephrologists in the province and knowing where everyone 
works, it would be hard not to know who seeing people was. The overall aim here is to 
identify pockets of disease within the province that are not accessing nephrology 
services with a view to subsequently starting an exploration of different ways to address 
any gaps identified. 
  
I would like to seek your permission to do this work given that you are part of the small 
group of nephrologists. 
  
If you have any comments on this project, please let me know. If you generally approve 
and would be willing to let this proceed as outlined, please let me know by reply to this 
email.  
 
  
Thanks.  
  
Looking forward to hearing from you. 
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Appendix B: Estimates of population (2011 Census and administrative data), by age 
group and sex for Newfoundland and Labrador, Regional Integrated Health Authorities 
2011-2016 
 
Geography Year 
Total, all 
ages 18-39 40-49 50-59 60-69 70+ 
NL 
2011 525,037 141,935 81,389 85,554 67,816 53,384 
2012 526,450 140,709 80,470 85,649 70,693 54,961 
2013 527,409 139,635 79,020 85,793 73,049 56,913 
2014 528,333 138,591 77,415 85,810 75,350 58,995 
2015 528,676 137,250 75,650 85,725 77,386 61,178 
        
ERIHA 
2011 313,618 91,560 48,017 49,286 38,416 29,570 
2012 315,647 91,438 47,661 49,523 40,225 30,325 
2013 317,567 91,679 46,927 49,755 41,586 31,493 
2014 319,622 91,892 46,169 50,013 42,983 32,678 
2015 321,008 91,640 45,533 50,092 44,243 33,888 
        
CRIHA 
2011 94,972 20,855 14,921 16,620 14,234 11,990 
2012 94,650 20,208 14,721 16,533 14,751 12,394 
2013 94,062 19,526 14,426 16,446 15,190 12,795 
2014 93,576 18,876 14,121 16,323 15,567 13,219 
2015 93,221 18,391 13,661 16,294 15,906 13,673 
        
WRIHA 
2011 79,218 18,472 12,295 13,971 11,340 9,371 
2012 78,823 18,069 11,964 13,954 11,713 9,699 
2013 78,519 17,611 11,640 13,922 12,129 10,006 
2014 77,967 17,159 11,256 13,811 12,509 10,355 
2015 77,457 16,807 10,730 13,721 12,804 10,733 
        
LGRIHA 
2011 37,229 11,048 6,156 5,677 3,826 2,453 
2012 37,330 10,994 6,124 5,639 4,004 2,543 
2013 37,261 10,819 6,027 5,670 4,144 2,619 
2014 37,168 10,664 5,869 5,663 4,291 2,743 
2015 36,990 10,412 5,726 5,618 4,433 2,884 
Source: Statistics Canada, CANSIM table 109-5355; (retrieved February 16, 2018) 
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Appendix C: Indigenous population proportion by community in Labrador-Grenfell 
health region, 2016 
 
118 
 
Appendix D: Patient’s Partner Invitation Letter 
 
 
 
Dr. Brendan Barrett MB, MSc, FRCPC  
Professor of Medicine (Nephrology) 
 
(On behalf of Dr. Mohammad A. Hossain, MBBS 
Masters student, Dept. of Clinical Epidemiology 
Memorial University of Newfoundland) 
 
 
 
Dear <Patient Partner’s Name> 
 
I contacted the Kidney Foundation to see if they might be able to find people with an 
interested in being involved in some kidney related research. They provided your name. 
 
If you are interested please let me know by reply. I would also need to know if you are 
comfortable with being identified to others who may have a similar interest through all 
of you collectively working together with me and a graduate student. 
 
 
 
Thanks for considering. 
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Appendix E: Adult incident dialysis patients, selected characteristics, Canada 
(excluding Quebec), 2008 to 2017 
Table 9  Adult incident dialysis patients, selected characteristics, Canada (excluding 
Quebec), 2008 to 2017 
      
Modality Characteristic 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
HD Mean age (years) 65.0 65.3 65.1 64.9 64.7 65.4 65.0 65.0 64.6 65.1 
HD Age 65+ (%) 56.5 57.3 56.0 56.7 55.5 57.0 56.0 56.7 55.9 57.7 
HD Male (%) 60.2 59.7 60.3 62.4 62.7 62.6 62.0 62.7 60.7 61.5 
HD Diabetes (%) 47.5 50.4 52.4 54.2 53.9 54.0 56.1 56.1 55.4 56.8 
HD Mean comorbidity 
index*  
1.9 2.1 2.0 2.2 2.1 2.0 2.1 2.2 2.1 2.0 
HD Mean BMI 28.2 28.4 28.4 28.3 28.9 29.2 29.0 29.3 29.1 29.3 
HD Mean eGFR† 10.3 10.7 10.6 10.6 10.4 10.3 9.9 10.1 10.3 10.1 
HD Late referral (%)‡ 36.3 36.5 34.4 33.8 30.6 31.9 31.8 30.8 31.4 30.3 
PD Mean age (years) 61.1 62.1 62.1 61.1 62.0 61.4 61.6 62.1 62.9 62.2 
PD Age 65+ (%) 45.1 46.0 47.3 43.7 46.1 45.3 45.4 48.8 50.6 50.1 
PD Male (%) 55.9 58.4 59.7 60.5 60.2 60.7 58.5 61.6 67.4 65.0 
PD Diabetes (%) 43.3 45.6 48.7 46.8 52.6 50.3 52.7 53.9 54.1 54.1 
PD Mean comorbidity 
index*  
1.1 1.1 1.3 1.2 1.2 1.1 1.3 1.2 1.4 1.2 
PD Mean BMI 27.7 28.2 27.5 27.5 28.0 27.5 27.9 28.1 27.9 28.0 
PD Mean eGFR† 10.6 10.8 10.9 10.2 10.0 9.9 9.5 9.5 9.4 9.6 
PD Late referral (%)‡ 10.4 10.1 8.9 10.2 7.0 7.7 7.4 7.7 7.5 6.9 
Notes:  
           
* The index assigns each of the 14 comorbid conditions collected in CORR a weight from 1 to 10. The 
possible range is from 0 to 32. 
† Estimated glomerular filtration rate (eGFR) as determined by the Modification of Diet in Kidney Disease 
(MDRD) formula (mL/min/1.73 m2). 
‡ Patients who first see a nephrologist less than 90 days before starting dialysis. 
BMI: Body mass index. 
Data from Quebec was excluded from this table because of significant under-reporting between 2011 and 
2017.  
Source: Canadian Organ Replacement Register, 2018, Canadian Institute for Health Information. 
 
